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ABSTRACT 
Androgens are steroid hormones that regulate the development and function of male 
reproductive organs as well as physiology of many non-reproductive tissues, such as 
muscle, bone, liver, and kidney. Moreover, androgen signaling is involved in several 
pathological conditions, most common of which is prostate cancer.  
 
In its target cells, testosterone or its more potent metabolite 5α-dihydrotestosterone 
regulates cellular processes by modulating gene expression through the androgen receptor 
(AR). Ligand-activated AR translocates to nucleus and binds to specific DNA sequences, 
called androgen response elements (AREs), at the regulatory regions of its target genes. 
AR cistromes, i.e., global maps of genomic AR occupancy, comprise thousands of AR-
binding events primarily located at distal enhancers. AR-binding sites are characterized 
by distinct histone modifications, and AR recruitment is primed by pioneer factors 
capable of binding to compact chromatin. AR interacts with a plethora of coregulatory 
proteins that modify the local chromatin environment and interact with basal transcription 
machinery. These elements create the complex cellular landscape for androgen action.  
 
The purpose of this thesis was to study molecular determinants of context-specific AR 
functions in vivo in murine androgen-responsive tissues. The advantage of in vivo studies 
is that – unlike in cancer cell models – androgen target cells reside within their 
physiological environment with an intact AR pathway. In the first part of this work, an 
androgen reporter mouse line with the luciferase gene under androgenic control was 
created. In this model, luciferase activity is a measure of AR function, and it can be used 
for assessing in vivo effects of chemical compounds on AR signaling. The androgen 
reporter mice were treated with genistein, a phytoestrogenic compound to which people 
consuming soy products are also exposed. Previous studies have implied that genistein 
plays a potential role in prostate cancer prevention. The results in this thesis work showed 
that genistein exhibits tissue-specific effects on AR signaling in vivo. Furthermore, 
genistein modulates endogenous AR-mediated gene expression in prostate, supporting its 
potentially beneficial role in prostate carcinogenesis. 
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In the second part of this work, genomic AR occupancy was examined using chromatin 
immunoprecipitation (ChIP) coupled with massively parallel sequencing (ChIP-seq). 
Distinct AR cistromes were identified in three androgen-responsive tissues: prostate, 
kidney, and epididymis. AR-binding events associate with tissue-specific transcription 
programs responsible for distinct physiological functions of androgens in these tissues. 
The key finding in this work was that tissue-specific AR binding is directed by divergent 
pioneer factors, and that previously identified forkhead box protein A1 (FoxA1) is 
prostate-specific rather than general pioneer factor for AR. Two novel pioneer factors for 
AR were identified in this study – hepatocyte nuclear factor 4 alpha (Hnf4α) in murine 
kidney and activating protein 2 alpha (AP-2α) in murine epididymis.  
 
ChIP-seq was also utilized to study in vivo role and characteristics of selective AREs – 
cis-elements not bound by other steroid receptors. Transgenic SPARKI mice have the 
second zinc finger of the AR DNA-binding domain swapped with the respective part of 
glucocorticoid receptor, resulting in a chimeric AR unable to bind to selective AREs. A 
significant proportion of in vivo binding events of wild-type AR were not shared by 
SPARKI AR in prostate and epididymis, highlighting the importance of selective AREs 
in AR-specific functions in vivo. Differential receptor binding was also linked to 
differentially expressed genes in the epididymides of wild-type and SPARKI mice. De 
novo sequence analysis revealed that the selective AREs are characterized by decreased 
sequence conversation, indicating that, counter-intuitively, AR selectivity in vivo is 
achieved by relaxed rather than increased cis-element stringency.  
 
In conclusion, both the AREs and the collaborating proteins contribute to precise AR-
regulated transcriptional outcome in the context of native chromatin and distinct tissues. 
Overall, the results clarified several molecular mechanisms employed by AR in vivo that 
can potentially contribute to the development of better treatments and diagnostic tools for 
hormone-dependent disorders in the future. 
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YHTEENVETO 
Steroidihormoneihin kuuluvat androgeenit säätelevät sekä miehen lisääntymiselinten 
kehittymistä ja toimintaa että useiden muiden kudosten, kuten munuaisten, lihasten ja 
luiden fysiologiaa. Normaalien fysiologisten säätelytehtäviensä lisäksi androgeenit 
vaikuttavat myös useiden sairauksien kehittymiseen, joista yleisin on eturauhassyöpä.  
 
Androgeenit säätelevät kohdesolujensa toimintaa aktivoimalla tai hiljentämällä tiettyjen 
geenien luentaa androgeenireseptorin (AR) välityksellä. AR on ligandin (hormonin) 
indusoima transkriptiotekijä, joka sitoutuu kohdegeeniensä säätelyalueille tunnistaen 
tietyn DNA-jakson, jota kutsutaan androgeenien vaste-elementiksi. AR:n vaikutus 
geenien luentaan välittyy vuorovaikutuksessa muiden säätelyproteiinien kanssa, ja 
yhdessä nämä muuttavat kromatiinin rakennetta ja toimivat transkriptiokoneiston kanssa. 
Aiemmat tulokset eturauhasen syöpäsoluista ovat osoittaneet, että AR sitoutuu tuhansiin 
säätelyelementteihin, jotka sijaitsevat tyypillisesti kaukana geenien promoottorialueista. 
Ennen reseptoria näille säätelyalueille sitoutuu usein ns. pioneeritekijä, eli proteiini, jonka 
ajatellaan avaavan tiukkaan paketoitua kromatiinirakennetta AR:n sitoutumista varten.  
 
Tässä väitöskirjassa AR:n toimintaa tutkittiin hiiren androgeenivasteisissa kudoksissa 
erilaisten hiirimallien ja modernien menetelmien avulla. Kromatiini-immunosaostukseen 
yhdistetyllä massiivisen rinnakkaisella DNA:n sekvensoinnilla (ChIP-seq) voidaan 
analysoida transkriptiotekijän DNA:n sitomispaikkoja koko genomin laajuudessa. 
Syöpäsoluviljelmiin verrattuna hiirikokeiden vahvuus on niiden mahdollistama AR:n 
vaikutusten tutkiminen fysiologisessa, monia solutyyppejä sisältävässä 
toimintaympäristössä.  
 
Tässä väitöskirjatyössä valmistettiin uusi siirtogeeninen hiirimalli, jossa androgeenit 
säätelevät ns. raportoijageenin ilmentymistä. Raportoijageenin aktiivisuutta mittaamalla 
voidaan tutkia erilaisten kemiallisten yhdisteiden vaikutusta AR:n toimintaan elävän 
hiiren kudoksissa. Raportoijahiiret altistettiin kasviestrogeeni genisteiinille, jota myös 
ihmiset saavat soijavalmisteita sisältävästä ravinnosta. Aiempien tutkimustulosten 
Yhteenveto 
 
 
 
 
6 
mukaan genisteiini saattaa alentaa riskiä sairastua eturauhassyöpään. Tämän työn tulokset 
osoittivat, että genisteiini vaikuttaa AR:n signalointiin kudosspesifisellä tavalla. Lisäksi 
havaittiin genisteiinin säätelevän AR-riippuvaisten geenien aktiivisuutta eturauhasessa, 
mikä tukee hypoteesia sen vaikutuksista eturauhassyövän kehittymiseen. 
 
Androgeenialtistuksen aikaansaamat AR:n genominlaajuiset sitoutumisprofiilit havaittiin 
hyvin erilaisiksi hiiren eturauhasessa, munuaisessa ja lisäkiveksessä. AR:n 
sitoutumispaikat liittyivät kudoskohtaisten geenien ilmentymiseen, selittäen androgeenien 
erilaisia fysiologisia vaikutuksia näissä kudoksissa. Aiemmissa soluviljelytutkimuksissa 
on havaittu FoxA1-proteiinin toimivan AR:n pioneeritekijänä ja toiminnan säätelijänä. 
Yksi tämän työn tärkeistä havainnoista on, että AR:n sitoutumista ohjaavat eri 
pioneeritekijät eri kudoksissa ja että FoxA1:n vaikutus rajoittuu eturauhaseen. Tässä 
työssä tunnistettiin kaksi uutta pioneeritekijää AR:lle: Hnf4α munuaisessa ja AP-2α 
lisäkiveksessä. 
 
Muut steroidireseptorit eivät sitoudu AR-selektiivisiin vaste-elementteihin in vitro-
olosuhteissa, ja tässä työssä niitä tutkittiin in vivo siirtogeenisen SPARKI-hiiren ja ChIP-
seq -menetelmän avulla. SPARKI-hiiren AR on kimeerinen proteiini, jonka DNA:ta 
sitovan osan toinen sinkkisormi on vaihdettu glukokortikoidireseptorin vastaavaan osaan, 
minkä johdosta SPARKI-AR ei sitoudu AR-selektiivisiin elementteihin. Merkittävä osa 
villityypin AR:n genominlaajuisista sitoutumispaikoista eturauhasessa ja lisäkiveksessä 
todettiin AR-selektiivisiksi in vivo -olosuhteissa. Yksi tämän työn mielenkiintoisista 
havainnoista on, että AR-selektiivisen DNA-sitoutumisen mahdollistaa reseptorin kyky 
sitoutua emäsjärjestykseltään vaihtelevampiin vaste-elementteihin kuin muut 
steroidireseptorit.  
 
Yhteenvetona tässä väitöskirjatyössä osoitettiin, että androgeenien aktivoiman AR:n 
vuorovaikutus säätelyalueiden vaste-elementtien ja kudosspesifisten pioneeritekijöiden 
kanssa on edellytys fysiologisesti tarkoituksenmukaiselle geenien ilmentymiselle. Uudet 
havainnot AR:n toiminnan molekyylimekanismeista voivat tulevaisuudessa mahdollistaa 
entistä parempien hoitomuotojen kehittämisen ihmisen hormoniriippuvaisiin sairauksiin.  
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ABBREVIATIONS 
AF   activation function 
AIS   androgen insensitivity syndrome 
AP   activating protein 
AR   androgen receptor 
ARE   androgen response element 
ARKO   androgen receptor knockout  
ATP   adenosine triphosphate 
ChIP-seq  chromatin immunoprecipitation coupled to deep sequencing 
CRPC   castration-resistant prostate cancer 
DBD   DNA-binding domain   
ER   estrogen receptor 
Fox   forkhead box 
GR   glucocorticoid receptor 
GRE   glucocorticoid response element 
HAT   histone acetyl transferase 
HDAC   histone deacetylase 
Hnf   hepatocyte nuclear factor 
HRE   hormone response element 
LBD   ligand-binding domain 
LSD   lysine-specific demethylase 
MR   mineralocorticoid receptor 
NR3C   nuclear receptor subgroup 3C 
NTD   amino (NH2)-terminal domain 
PBX1   pre-B-cell leukemia homeobox 1 
PPAR   peroxisome proliferator-activated receptor  
PR   progesterone receptor 
PTM   post-translational modification 
SBMA   spinal and bulbar muscular atrophy 
siRNA   small interfering RNA 
Slp   sex-limited protein 
SPARKI  specificity-affecting androgen receptor knock-in 
SRC   steroid receptor coactivator 
TBP   TATA-binding protein 
Tfm   testicular feminization 
TR   thyroid hormone receptor 
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INTRODUCTION 
Androgens orchestrate the development of male phenotype and serve as important 
physiological regulators in many non-reproductive tissues. Many developmental events 
require androgens during a discrete time window, whereas reproductive functions are 
androgen-dependent throughout the life. Androgen receptor (AR), the mediator of 
androgen action, belongs to the nuclear receptor superfamily with distinct structural 
domains that define their molecular action as ligand-inducible transcription factors.  
 
The essential function of androgen-activated AR is to bind to its response elements at the 
regulatory regions of the AR target genes, and to induce or repress their transcription in 
collaboration with coregulatory proteins and transcription machinery. The overall picture 
of nuclear receptor action, however, involves interplay of multiple signaling pathways in 
the cellular environment. Cellular steroid metabolism, as well as expression pattern and 
functional consequence of coregulators and other collaborating proteins define the 
context-specific transcriptional outcome. Post-transcriptional modifications alter 
activities of the receptors and create the chromatin landscape that regulates all DNA-
templated processes. Cellular effects of androgens are further amplified through 
secondary effects, when primary androgen target genes regulate new sets of genes or 
modulate other signaling pathways, for example, by inducing changes in signaling by 
other hormones, such as the growth hormone.  
 
The physiological importance of AR pathway and its role in human pathological 
conditions make it pertinent to study AR action. Moreover, ligand-inducible AR signaling 
provides an interesting pathway that potentially reveals new insights into general 
mechanisms and molecular determinants of transcriptional regulation. Full appreciation 
of the complexity of biological signaling requires in vivo studies in a physiological 
context. Vast knowledge on mouse genomics and physiology as well as sophisticated 
genome manipulating methods underline the benefits of the mouse as a model system. In 
this thesis work, state-of-the art methods have been utilized to study in vivo aspects of 
androgen-dependent transcriptional regulation in murine tissues. 
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REVIEW OF THE LITERATURE 
1. Signal transduction and nuclear receptors 
1.1 Overview of signal transduction 
Development and function of multicellular organisms rely on specific and timely 
communication between the cells. Individual cells within an organism share the same 
genome, but display highly variable morphology, life span and functional characteristics. 
By and large, biological signaling utilizes extracellular molecules that are recognized by 
specific receptor proteins located on the plasma membrane or within the target cells. 
Autocrine or intracrine signals affect the same cell that produces the signal molecules, 
paracrine signals are transmitted to nearby cells, and endocrine signals, the hormones, are 
distributed to the whole organism via bloodstream. The receptor proteins bind distinct 
chemical entities determined by their molecular structure and activate intracellular 
signaling pathways leading to changes in cellular metabolism and growth. Ligands are 
usually small molecules such as peptides, neurotransmitters, hormones, dietary and 
metabolic compounds, or toxins. Agonistic ligands activate the receptor, whereas pure 
antagonists bind the receptor without activating it, thus preventing activation by agonist 
binding. Inverse agonists, on the other hand, induce responses that are opposite to the 
agonist effect. Under the physiological conditions, many compounds exhibit more diverse 
effects on receptors with a range of agonistic and antagonistic properties, depending on 
the cellular context. Complex interplay of various signaling pathways and intracellular 
conditions creates distinct cellular phenotypes during development and results in a 
multicellular organism capable of adaptation and responsiveness. 
1.2 Intracellular signaling by nuclear receptors 
A distinct class of intracellular signaling molecules, the nuclear receptor superfamily, 
comprises transcription factors that share structural and functional characteristics. 
Modular structure of nuclear receptors with separate domains for DNA- and ligand-
binding enables them to act as molecular switches that recognize endocrine or metabolic 
signals and mediate their effects to cellular processes by binding to DNA and modulating 
  Review of the literature 
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gene expression (Nagy and Schwabe, 2004). The human and mouse genomes include 48 
and 49 genes encoding nuclear receptors, respectively, and their physiological functions 
encompass metabolism and energy homeostasis, as well as reproduction, development, 
and growth (Bookout et al., 2006). Classically, nuclear receptors have been divided into 
three categories: steroid hormone receptors (Class I), such as estrogen receptor (ER) and 
AR; receptors with non-steroidal ligands and with ligands that are lipid metabolites, such 
as thyroid hormone receptor (TR) and peroxisome proliferator-activated receptors 
(PPARs), respectively (Class II); and orphan receptors with no recognized ligand (Class 
III). However, ligands have been identified for numerous orphan receptors in recent 
years, and an alternative classification based on evolutionary conservation and sequence 
homology distinguishes six subfamilies of nuclear receptors (Germain et al., 2006).  
 
The modular structure characteristics of nuclear receptors involve four distinct domains 
(Figure 1): amino-terminal domain (NTD, A/B domain), DNA-binding domain (DBD, C-
domain), hinge region (D-domain), and ligand-binding domain (LBD, E-domain) 
(Aranda and Pascual, 2001). NTD is the most variable domain both in size and sequence, 
and it usually contains a ligand-independent transcriptional activation function (AF-1) 
that can operate autonomously. DBD, the most conserved domain of the nuclear 
receptors, makes specific high-affinity contacts with DNA using two zinc fingers and is 
also responsible for receptor dimerization upon activation. Hinge region connects DBD 
and LBD, and it usually contains the nuclear localization signal. LBD of each receptor 
binds its physiological ligand with high specificity due to variability in the size, shape 
and distribution of polar and non-polar residues within the ligand-binding pocket (Jin and 
Li, 2010). LBD also harbors AF-2, whose conformation and activation are strongly 
dependent on ligand binding. 
 
 
 
Figure 1. Functional domains of nuclear receptors with their main functions highlighted. Amino-
terminal domain (NTD), DNA-binding domain (DBD), ligand-binding domain (LBD). 
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Unliganded nuclear receptors reside either in the cytoplasm or in the nucleus. Thus, their 
ligands have to be small hydrophobic compounds that are able to diffuse through the 
plasma membrane. Ligand binding activates the receptor and promotes its interaction 
with coactivator proteins followed by recruitment of basal transcription machinery, and 
ligand-inducible gene activation. Many Class II nuclear receptors such as TR and retinoic 
acid receptor are constitutively bound to chromatin and associate with transcriptional 
repressors in the absence of a ligand, leading to active gene repression (Germain et al., 
2006). Unliganded steroid receptors, however, reside preferably in the cytoplasm and 
ligand binding induces their nuclear translocation, leading to both gene activation and 
repression through interaction with coactivators and corepressors, respectively. In 
transrepression, a nuclear receptor inhibits gene expression through other transcription 
factors. For example, glucocorticoid receptor (GR) suppresses inflammation by tethering 
to nuclear factor kappa B, thus preventing coregulator binding (Glass and Saijo, 2010). 
The precise transcriptional outcome achieved by nuclear receptors requires contributions 
from chromatin remodelers, histone and DNA modifying enzymes, collaborating 
transcription factors, coregulators, and basal transcriptional machinery, which will be 
discussed in the following chapters of this literature review. 
1.3 Nuclear receptors and coregulators 
Eleven alpha helices constitute the ligand-binding pocket of the nuclear receptor LBD. 
Helix 12 forms a mobile lid over the pocket, and its conformation is determined by the 
presence or absence of the ligand. Agonist binding exposes LxxLL motif (where L is 
leucine and x is any amino acid) for protein-protein interaction. As a result, nuclear 
receptor dissociates from corepressors and recruits coactivators, many of which also 
contains LxxLL motifs that interact with the LBD (Heery et al., 1997). Coactivators then 
modify local chromatin environment and interact with the basal transcription machinery 
promoting formation of the preinitiation complex at the gene promoter. Histone 
acetylation correlates strongly with active, open chromatin, and many coactivator 
proteins are histone acetylases (HAT). Conversely, histone deacetylation is associated 
with inactive chromatin state, and many corepressors possess histone deacetylase 
(HDAC) activity. To date, over 350 nuclear receptor coregulators have been reported in 
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the literature (Lonard and O'Malley, 2012). Typically, they form large complexes at gene 
regulatory regions collaborating with nuclear receptors in a cell-type and DNA-binding 
site-dependent manner (Rosenfeld et al., 2006). Moreover, classification into coactivators 
and corepressors seems to be context-dependent. For instance, HDAC1 that is a classical 
corepressor due to its histone deacetylase activity was reported to serve as coactivator for 
GR (Qiu et al., 2006), and steroid receptor coactivator (SRC)-2 was found to be an ERα-
corepressor in tumor necrosis factor α-mediated transcription (Cvoro et al., 2006).  
 
Compact nucleosomal assembly of inactive chromatin hinders all DNA-templated 
processes. Thus, chromatin reorganization is an indispensable part of the dynamic 
transcriptional control by nuclear receptors. Coregulators can be divided into functionally 
divergent classes depending on their role in chromatin reorganization (Kato et al., 2011). 
First, chromatin remodelers modify the histone-DNA interface by using the energy from 
adenosine triphosphate (ATP) hydrolysis, leading to loosening of tightly coiled chromatin 
and generating local chromatin environment open for transcription factor binding, or by 
condensing chromatin structure and promoting gene repression (Clapier and Cairns, 
2009). The second group comprises enzymes that covalently modify histones. Various 
reversible post-translational modifications (PTMs) have been identified at histone tails – 
for instance acetylation, methylation, phosphorylation, ubiquitylation, and sumoylation – 
but evidence for serving as nuclear receptor coregulators has mostly accumulated for 
acetylases, deacetylases, methylases, and demethylases (Kato et al., 2011). The 
coregulator proteins itself, as well as nuclear receptors, are subject to similar enzymatic 
PTMs that regulate their activities and function, adding another layer of complexity to the 
context-dependent transcriptional regulation and prospects for crosstalk with other 
signaling pathways.  
1.4 Physiological functions of nuclear receptors 
Nuclear receptors are ubiquitous in the metazoan kingdom, but absent in fungi and plants. 
They regulate a wide range of physiological processes from reproduction, development, 
and growth to nutrient uptake, metabolism, and excretion (Figure 2), and each receptor 
has important and nonredundant functional roles (Germain et al., 2006). Nuclear 
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receptors involved in reproductive functions include, for example, Class I receptors for 
sex steroids – estrogens, progestins, and androgens – that govern gender-specific traits 
and sexual reproduction, as well as Class III orphan receptors – steroidogenic factor-1 
(SF-1) and DAX-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenital critical 
region on the X chromosome, gene 1) – that regulate steroidogenesis and other 
reproductive functions both in adults and during embryonic development (Achermann et 
al., 2001). Various nuclear receptors are key regulators of metabolic pathways, such as 
vitamin D receptor (VDR) for dietary calcium uptake and metabolism, farnesoid X 
receptor α (FXRα) for bile acid metabolism, estrogen-related receptor α (ERRα) for 
oxidative gene expression driving mitochondrial energy utilization, and TRβ for body 
temperature and fatty acid and cholesterol metabolism (Bookout et al., 2006).  
 
 
Figure 2. Expression–function relationship of nuclear receptors. Physiological functions of the 49 
murine nuclear receptors identified on the basis of their expression profiles in 39 tissues. CNS, 
central nervous system. Reprinted from Bookout et al., Anatomical profiling of nuclear receptor 
expression reveals a hierarchical transcriptional network, Cell 126:789–799, 2006, with 
permission from Elsevier (copyright 2006). 
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GR is also an important regulator of metabolism promoting lipolysis and 
gluconeogenesis, as opposed to PPARγ that supports actions of insulin and facilitates fat 
storage. Both GR and PPARγ are also important anti-inflammatory factors highlighting 
the integration of metabolic and immune systems as a central homeostatic mechanism, 
dysfunction of which can lead to chronic metabolic disorders, such as obesity, type 2 
diabetes and cardiovascular disease (Hotamisligil, 2006). Specific endocrine organs 
produce the steroid and thyroid hormones that serve as high-affinity ligands for their 
cognate receptors, capable of eliciting maximal physiological responses at nanomolar 
concentrations. However, along with the discovery of ligands for many of the “orphan” 
receptors, it has become clear that nuclear receptors can also function as sensors for either 
metabolic or environmental signals (Sladek, 2011). For instance, retinoid receptors bind 
vitamin A formed from exogenously obtained β-carotene, and the endogenous ligands for 
PPARs – various fatty acid derivatives – are metabolic signals available at micromolar 
range.  
 
Important physiological roles of nuclear receptors also link them to many pathological 
conditions, and the ligand-binding pocket that regulates nuclear receptor functions makes 
them appealing targets for drug development. For instance, sex steroids are involved in 
pathogenesis of hormone-dependent malignancies, and compounds that antagonize 
estrogenic and androgenic effects are widely used to treat breast and prostate cancer, 
respectively. Glucocorticoids are effective immunosuppressants in various conditions, 
and modulators of ER and progesterone receptor (PR) can be used as hormonal 
contraceptives. Ligands for nuclear receptors that regulate metabolic pathways hold great 
promise for treating metabolic disorders. The PPARγ agonist rosiglitazone is an effective 
insulin sensitizer in type 2 diabetes, although the occurrence of severe side effects has 
limited its clinical use. Better understanding of nuclear receptor function and mechanistic 
insight provided by modern research methods can help in developing new drugs targeting 
this versatile family of transcription factors.   
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2. Transcription 
2.1 Gene transcription and transcription factors  
Genomic DNA encompasses hereditary information in two fundamental ways: 
transcribed regions provide template for proteins and functional RNA molecules, and 
regulatory DNA elements contain instructions for their appropriate expression patterns. A 
gene can be defined as a unit of heredity comprising the transcription unit and regulatory 
elements needed for producing a single protein or RNA. However, delineating a 
comprehensive set of regulatory elements corresponding to expression of a defined 
transcription unit is not straightforward and is a subject to intensive research efforts. The 
ENCODE Consortium has characterized functional elements in 147 cell types, and 
recently reported that 80% of the genome contains elements linked to biochemical 
functions (The ENCODE Project Consortium, 2012), highlighting the complexity and 
versatility of gene regulatory elements. Moreover, the cumulative coverage of transcribed 
regions across the human genome is about 75%, and the genes are highly interlaced with 
overlapping transcripts that are synthesized from both DNA strands (Djebali et al., 2012).  
 
Regulatory elements of eukaryotic genes – promoters, enhancers, silencers, and insulators 
– ensure precise, cell type- and context-specific gene transcription. Regulatory regions 
contain cis-acting DNA elements that recruit trans-acting regulatory proteins, such as 
nuclear receptors, that bind to these elements establishing a network of gene regulation. 
Promoters are DNA sequences located next to transcription start site that direct RNA 
polymerase to initiate transcription at the correct place. Distal regulatory elements, 
enhancers and silencers, are defined by their functional consequence to gene regulation, 
and they can act independently of position or orientation, from a distance of hundreds of 
kilobases or even from different chromosomes (Lomvardas et al., 2006). Enhancers serve 
as binding platforms for lineage-specific transcription factors and sequence-specific 
effectors of signaling pathways, integrating information about intracellular conditions and 
cellular environment to combinatorial response in gene expression patterns (Calo and 
Wysocka, 2013). Distant enhancers dictate cell type-specific gene activation in both 
human and mice, as shown by recent genome-wide studies of transcription factor 
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cistromes and histone modifications (Heintzman et al., 2009; Shen et al., 2012). 
Insulators impede the effects of long-range regulatory elements by blocking the enhancer 
activity to unrelated promoters, and the vertebrate insulators are characterized by 
CCCTC-binding factor binding (Bell et al., 1999). 
2.2 Basal transcriptional apparatus  
All eukaryotic protein-coding genes are transcribed by RNA polymerase II, a large 12-
subunit enzyme complex that is assisted by general transcription factors. Sequence-
specific transcription factors bound to enhancers and promoters initiate a complex and 
highly dynamic process of gene activation that culminates in the formation of a 
preinitiation complex containing over 100 individual protein subunits. A protein complex 
known as mediator allows distal enhancer sites to get in contact with a gene promoter. 
Formation of the preinitiation complex at the core promoter is initiated by TATA-binding 
protein (TBP), followed by ordered assembly of other general transcription factors and 
RNA polymerase II. Classical cis-element for TBP is the so-called TATA box, but recent 
genome-wide analysis identified a 50-bp signature sequence at gene promoters that 
defines TBP binding and the preinitiation complex formation to be enriched with mostly 
other sequence motifs than the TATA box (Neph et al., 2012). The core promoter 
determines the point and direction of transcription initiation, and general transcription 
factors then orchestrate unwinding of double-stranded DNA and enable transcriptional 
initiation and elongation by RNA polymerase II in the context of chromatin and 
nucleosomes (Barski et al., 2007; Li et al., 2012a).  
2.3 Chromatin structure and function 
Eukaryotic DNA is tightly packaged inside the nucleus in the form of chromatin 
(Kornberg, 1974). A nucleosome comprises two copies of each of the canonical histone 
proteins (H3, H4, H2A and H2B) or their variants, and a 147-bp stretch of DNA wrapped 
around them. Nucleosomes are joined together by linker histones, and the string of 
nucleosomes is packaged to higher-order structures (Schwarz and Hansen, 1994). The 
compact structure of chromatin occludes gene transcription and other DNA-templated 
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processes, and the dynamic nature of chromatin provides an important regulatory step in 
making DNA accessible to these activities (Banaszynski et al., 2010).  
 
Nucleosome positioning, i.e., the location of nucleosomes along the DNA stretch, is 
determined by several factors: the DNA sequence, ATP-dependent nucleosome 
remodelers, and transcription factors, such as activators, components of preinitiation 
complex, and the elongating RNA polymerase II (Bell et al., 2011). DNA sequence that 
is stiff in structure, such as homopolymers of identical bases, is resistant to nucleosome 
formation, whereas more a bendable sequence makes more stable contact with the histone 
octamer and is more likely to be involved in nucleosomal structure (Segal et al., 2006). 
Chromatin remodeling enzymes utilize energy from ATP hydrolysis to change the 
chromatin structure by sliding, evicting or restructuring the nucleosomes, thus 
contributing to nucleosome packaging and spacing as well as regulatory mechanisms of 
transcription (Clapier and Cairns, 2009). Other mechanisms altering chromatin structure 
are the use of covalent histone modifications (Li et al., 2007) and less stable histone 
variants (Banaszynski et al., 2010). Transcription start sites often reside in nucleosome-
free regions (Segal et al., 2006), and especially H3.3 and H2A.Z double-variant histones-
containing nucleosomes are found flanking transcription start sites of active genes (Jin et 
al., 2009). Labile H2A.Z variant is also enriched at distal enhancers, as demonstrated by a 
recent study in a prostate cancer cell line with the ligand-inducible AR binding leading to 
eviction of the central nucleosome (He et al., 2010). 
 
Histone proteins possess unstructured amino-terminal tails that are subject to highly 
variable covalent modifications. Multiple residues in each histone can be modified, and 
the diversity of modifications includes acetylation, phosphorylation, methylation, 
deimination, β-N-acetylglucoseamination, adenosine diphosphate ribosylation, 
ubiquitylation, and sumoylation. One mechanism by which the modifications alter the 
chromatin structure is to change the net charge of nucleosomes. Acetylation of lysines 
and phosphorylation of serine, threonine, and tyrosine residues reduce the positive charge 
of the histones and thus loosen electrostatic interactions between histones and DNA, 
leading to less compact chromatin structure. Thus, histone acetylation is often associated 
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with transcription factor-binding sites and transcriptionally competent environment, and 
in vivo binding of the histone acetylase p300 demarcates active, tissue-specific enhancers 
(Visel et al., 2009). Secondly, combinations of histone modifications can serve as binding 
platforms for various non-histone proteins creating a histone code that regulates DNA-
templated processes (Strahl and Allis, 2000). The map of histone modifications is brought 
about by enzymes that catalyze addition or removal of specific modifications in a residue-
specific manner. The histone code is interpreted into meaningful biological outcome by 
specific proteins, such as chromatin remodeling enzymes that recognize selective 
combinations of modified histones and subsequently drive distinct nuclear processes 
(Calo and Wysocka, 2013; Li et al., 2007). As mentioned in Chapter 1.3, many of the 
histone modifying enzymes are nuclear receptor coregulators that are recruited to gene 
regulatory elements by hormone-dependent transcription factor binding. 
 
Genome-wide mapping of various histone modifications and their correlation to genomic 
features and transcription factor-binding sites has greatly improved our understanding 
about the epigenetic map encoded in histone tails. Especially lysine methylation plays an 
important role in creating the histone code, as there are more distinct protein domain 
types recognizing lysine methylation than any other modification, and the 
methyltransferases are among the most specific histone-modifying enzymes (Bannister 
and Kouzarides, 2011). Active enhancers are characterized by monomethylation of lysine 
4 in histone 3 (H3K4me1), whereas trimethylation of the same residue (H3K4me3) is 
predominantly found at gene promoters (Barski et al., 2007; Heintzman et al., 2007). 
Conversely, methylation of lysines 9 and 27 in histone 3 is associated with transcriptional 
repression (Roh et al., 2006). Thus, the functional consequence of histone methylation is 
highly dependent on the chromatin context and the modified residue. This is also 
demonstrated by the diverse roles of lysine-specific demethylase 1 (LSD1) in AR 
signaling: LSD1 promotes AR-dependent transcriptional activation by demethylating 
lysine 9 in histone 3 (H3K9) (Metzger et al., 2005), but it was recently shown to repress 
AR gene expression in an androgen-dependent fashion through H3K4me2 demethylation 
(Cai et al., 2011). Summary of covalent histone modifications and their putative roles in 
gene transcription is presented in Table 1.  
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Table 1. Covalent histone modifications involved in transcriptional regulation. Adapted from Li 
et al., The role of chromatin during transcription, Cell 128:707–719, 2007, with permission from 
Elsevier (copyright 2007) and from The ENCODE Project Consortium, An integrated 
encyclopedia of DNA elements in the human genome, Nature 489:57–74, 2012, under Creative 
Commons license (copyright 2012).  
Modification Putative functions 
H3K4me1 Mark of enhancers and other distal elements, but also enriched downstream of TSS 
H3K4me2 Mark of regulatory elements associated with promoters and enhancers 
H3K4me3 Mark of regulatory elements primarily associated with promoters/TSS 
H3K9ac Mark of active regulatory elements with preference for promoters 
H3K9me1 Preference for the 5′ end of genes 
H3K9me3 Repressive mark associated with constitutive heterochromatin and repetitive elements 
H3K27ac Active mark; may distinguish active enhancers and promoters from inactive ones 
H3K27me3 Repressive mark established by polycomb complex activity  
H3K79me2 Transcription-associated mark, with preference for 5′ end of genes 
H3R2,R17,R26me Transcriptional activation 
H4K20me1 Preference for 5′ end of genes 
H4K16ac Transcriptional activation 
H2AK119ub Transcriptional repression 
H2BK120/K123ub Transcriptional activation 
TSS=transcription start site, me=methylation, ac=acetylation, ub=ubiquitylation  
2.4 Genome-wide approaches to study transcription 
Massively parallel next-generation sequencing has revolutionized the ways by which 
transcription can be studied. The previous gene-centric approaches concentrated on a few 
genes and genomic loci at a time, whereas massively parallel sequencing allows an 
unbiased genome-scale analysis of DNA fragments in a quantitative fashion, generating a 
global picture of chromatin state, histone modifications, or transcription factor binding. 
Chromatin immunoprecipitation (ChIP) is a method where a transcription factor or other 
chromatin-associated protein is enriched from cross-linked chromatin using a specific 
antibody (Solomon et al., 1988), and the DNA co-precipitated with the protein of interest 
is then analyzed by using region-specific primers (ChIP-qPCR), by hybridizing 
fluorescently labeled DNA to genomic microarrays (ChIP-on-chip) (Ren et al., 2000), or 
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by high-throughput DNA sequencing (ChIP-seq) (Barski et al., 2007; Johnson et al., 
2007). Cistrome is a term for a set of cis-acting targets of a trans-acting factor on a 
genome-wide scale, usually determined using ChIP-seq. In addition, there are several 
high-throughput methods for analyzing nucleosome occupancy and DNA accessibility 
(DNaseI-seq, FAIRE-seq), nucleosome positioning (MNase-seq) and long-range 
chromatin interactions (Bell et al., 2011) (Figure 3). Combined with gene expression 
profiles generated using either array technology or RNA-sequencing, next-generation 
sequencing approaches provide a comprehensive view of transcriptional landscape in 
cells or tissues of interest under defined conditions (Zhou et al., 2011). The wealth of 
data produced by high-throughput experiments has greatly improved our understanding 
of transcriptional regulation. However, the present genome-wide methods study cell 
populations at a fixed time-point, and getting a more dynamic picture of transcriptional 
events remains a future challenge (Coulon et al., 2013). In this thesis, genome-wide 
methods have been utilized to study androgen-dependent transcription programs. 
 
 
Figure 3. Chromatin structure, gene regulatory elements and genome-wide methods to study 
transcription (methods highlighted in red). Chromosomal DNA is protected from degradation by 
endonucleases, whereas linker regions are digested by micrococcal nucleases (MNase) and 
regulatory DNA elements are sensitive to DNase I digestion. In formaldehyde-assisted 
identification of regulatory elements (FAIRE) nucleosomal DNA is cross-linked and nucleosome-
free accessible DNA analyzed. Genome-wide maps of transcription factor binding and chromatin 
modifications can be obtained using ChIP-seq with specific antibodies, and gene expression 
profiles by RNA-seq or microarrays. Chromosome conformation capture assay (Hi-C) reveals 
higher-order chromatin structures using restriction digestion and ligation of cross-linked 
chromatin, and high-throughput data is achieved by paired-end tag sequencing (ChIA-PET).  
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3. Steroid receptor-mediated signaling 
3.1 Steroid hormones and receptors 
Steroid hormones are small lipophilic molecules derived from cholesterol in a series of 
enzymatic reactions catalyzed by various cytochrome P450 and hydroxysteroid 
dehydrogenase enzymes (Payne and Hales, 2004). Glucocorticoids and 
mineralocorticoids are synthetized in adrenal cortex, and progesterone, estradiol, and 
testosterone mainly in gonads. Steroid hormones act as chemical messengers modulating 
a wide variety of physiological processes, and they exert their functions by binding with 
high affinity and high specificity to their cognate receptors: ERα, ERβ, PR, AR, GR, and 
mineralocorticoid receptor (MR). The primary mode of steroid receptor action is through 
genomic regulation of the target gene expression, but there is a growing body of evidence 
for non-genomic steroid receptor actions through cytoplasmic signaling pathways. 
However, these rapid effects appear to have a minor role in androgen signaling and have 
not yet been well-characterized. The chemical structures of steroids are very similar 
(Figure 4), and as lipophilic compounds, they are transferred in circulation bound to 
albumin and high-affinity proteins, corticosteroid-binding globulin and sex hormone-
binding globulin (Hammond, 2010).  
 
Figure 4. Chemical structures of primary physiological steroid hormones in human. 
 
Structural and mechanistic data accumulated since cloning of the first steroid receptors, 
GR (Hollenberg et al., 1985) and ER (Green et al., 1986; Greene et al., 1986), have 
expanded our understanding of hormone action and gene regulation by sequence-specific 
transcription factors. Evolutionarily, steroid receptors appear to originate from a single 
ER-like ancestral receptor, and the six vertebral steroid receptor genes are products of 
gene duplications (Eick and Thornton, 2011). GR, MR, PR, and AR – the subclass NR3C 
of the nuclear receptor superfamily – have evolved to bind various 3-ketosteroids, 
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intermediates of estradiol synthesis, by molecular exploitation (Eick and Thornton, 2011). 
Estradiol, progesterone, and testosterone are critical regulators of reproductive functions 
through their cognate receptors, ERα, ERβ, PR, and AR. Endogenous glucocorticoids, 
cortisol in human and corticosterone in rodents, mediate their effects to various metabolic 
and inflammatory processes through GR. Mineralocorticoids, such as aldosterone, affect 
transepithelial sodium transport and regulate blood pressure and sodium homeostasis by 
increasing sodium reabsorption in the nephrons. As opposed to high ligand-specificity of 
other steroid receptors, MR binds both cortisol and aldosterone with a similar affinity. 
Mineralocorticoid selectivity is achieved by conversion of cortisol to cortisone that is 
unable to bind to MR in mineralocorticoid target cells by 11β-hydroxysteroid 
dehydrogenase type 2 (Edwards et al., 1988; Funder et al., 1988). 
3.2 Steroid receptor-mediated transcription 
Molecular chaperones, such as heat-shock proteins Hsp90 and Hsp70, keep cytoplasmic 
unliganded steroid receptors in a conformation permitting hormone binding. Ligand 
binding alters receptor conformation, leading to its dissociation from the chaperone 
complex and unmasking of the nuclear localization signal. Nevertheless, chaperones and 
co-chaperones are required for proper folding, trafficking, transcriptional activation, and 
degradation of the steroid receptors (Echeverria and Picard, 2010). Interestingly, 
molecular chaperones also promote disassembly of nuclear receptors from DNA 
regulatory elements, enabling responsiveness to changing hormone concentration 
(Freeman and Yamamoto, 2002).  
 
In the nucleus, steroid receptors bind to their cognate response elements that are located 
primarily at distal enhancers, as demonstrated by numerous studies since the first ChIP-
on-chip reports for ERα and AR (Carroll et al., 2005; Carroll et al., 2006; Wang et al., 
2007). Multiple amino acid residues throughout the receptor DBD make non-specific 
contacts with the DNA backbone, whereas the sequence-specific contact with DNA is 
mediated by few amino acids in the P box of the DNA recognition helix in the first zinc 
finger (Luisi et al., 1991; Schwabe et al., 1993). The P box of GR, MR, AR, and PR 
comprises identical residues, and all of them bind similar hormone response elements 
Review of the literature 
 
 
 
 
24 
(HRE) – inverted repeats of the 5’-AGAACA-3’ consensus sequence with a 3-nt spacer –
, whereas the P box and the response element sequence of ER are different from those of 
the other steroid receptors (Cotnoir-White et al., 2011). Mutations in the first hexamer of 
the HRE have greater impact on receptor binding than those in the second hexamer, 
indicating that the first hexamer serves as a high-affinity docking site for steroid receptors 
(Helsen et al., 2012; Verrijdt et al., 2000). The first androgen-selective response element 
identified at the enhancer of the mouse sex-limited protein (Slp) gene implied that 
differences in the cis-element sequence contribute to the receptor-specific DNA binding 
(Adler et al., 1992; Adler et al., 1993). In transient transfection assays, AR, GR, MR, and 
PR are all capable of transactivating reporter gene expression through the canonical 
androgen/glucocorticoid response element (ARE/GRE), whereas only AR and to some 
extent PR bind to so-called selective AREs that resemble direct repeats of the consensus 
sequence (Claessens et al., 1996; Denayer et al., 2010; Schoenmakers et al., 1999). 
Interestingly, DNA can also serve as an allosteric ligand for steroid receptors, as DNA 
sequence has been shown to affect GR structure and function (Meijsing et al., 2009; 
Watson et al., 2013). 
 
Despite their similar response elements and related protein structures, steroid receptors 
exert diverse physiological functions and regulate their own target genes. Various ChIP-
seq studies have reported distinct binding profiles for steroid receptors in a genuine 
chromatin environment, yet the cis-elements identified thus far for AR, PR, GR, and MR 
highly resemble the canonical ARE/GRE (Ballare et al., 2013; Grøntved et al., 2013; 
John et al., 2011; Lain et al., 2013; Massie et al., 2011; Rubel et al., 2012; Sahu et al., 
2011; Sahu et al., 2013; Ueda et al., 2014). Thus, the determinants of in vivo binding 
specificity of the NR3C family steroid receptors are still enigmatic, and multiple cis-
elements within the context of one enhancer can contribute to the specificity and extent of 
the physiological response (Robins, 2005; Verrijdt et al., 2002). Moreover, potential 
crosstalk between different steroid receptors expressed in the same cell types has recently 
gathered growing interest. About 50% of AR-occupied enhancers in prostate cancer cells 
can also be bound by GR, and GR is able to modulate the AR-signaling pathway (Arora 
et al., 2013; Sahu et al., 2013). Dexamethasone-liganded GR elicits redistribution of ER 
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binding on a genome-wide scale in murine mammary gland epithelial cells (Miranda et 
al., 2013), demonstrating molecular interplay between steroid receptor pathways. 
Furthermore, estradiol- and progesterone-induced transcriptional programs are largely 
overlapping in bovine liver, suggesting that these hormones have partly redundant roles 
in this tissue (Piccinato et al., 2013).  
 
Transcription factors typically occupy only few percent of their putative binding sites 
(cis-elements), highlighting the importance of factors other than the DNA sequence for 
specific chromatin binding (Joseph et al., 2010; Kaplan et al., 2011). Moreover, many 
nuclear proteins are highly mobile, with the residence time on DNA from ten seconds to 
one minute for steroid receptors, as judged by live single-cell microscopy with 
fluorescent probes (McNally et al., 2000; van Royen et al., 2011). This suggests that 
individual components of transcriptional protein complex exchange rapidly, although the 
productive complex at the regulatory element stays longer (Karpova et al., 2008). Finally, 
interplay of local chromatin structure, collaborating transcription factors, and 
coregulators determines the receptor-selective transcriptional outcome in vivo (Wiench et 
al., 2011b). 
3.3 Pioneer factors for steroid receptors 
Arrangement of DNA into nucleosomal chromatin occludes regulatory elements from 
transcription factor binding. Pioneer factors are a special class of transcription factors that 
are able to bind to condensed chromatin and prime target loci in the genome for other 
factors to bind (Zaret and Carroll, 2011). The first pioneer factors, forkhead box (Fox)A 
and GATA proteins, were reported to precede other transcription factors in chromatin 
binding and to be indispensable for liver differentiation program (Gualdi et al., 1996; Lee 
et al., 2005; Watt et al., 2007). The FoxA proteins belong to the Fox family of winged 
helix transcription factors, and their unique properties can facilitate DNA binding of other 
transcription factors. The DBD of FoxA proteins resembles that of a linker histone, 
allowing them to bind to nucleosomal DNA (Cirillo et al., 1998; Clark et al., 1993), and 
their carboxyl-terminal domain binds directly to core histones facilitating the opening of 
nucleosomal DNA structure (Cirillo et al., 2002). FoxA1 recognizes a specific cis-
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element on DNA. However, pioneer factors are also thought to function as readers of the 
histone code, translating epigenetic modifications into specific transcription factor 
binding (Magnani et al., 2011b). Moreover, FoxA1 also has a transactivation domain that 
can recruit coregulators to modify local chromatin environment (Zaret and Carroll, 2011). 
The role of FoxA1 in steroid receptor function has been highlighted by multiple recent 
genome-wide studies, especially for ERα function in breast cancer cells and AR function 
in prostate cancer cells (Augello et al., 2011). Characteristic features of genome-wide 
FoxA1 binding are the significant overlap with ERα and AR cistromes and the binding to 
these sites prior to hormone-induced receptor loading (Eeckhoute et al., 2006; Hurtado et 
al., 2011; Lupien et al., 2008; Robinson et al., 2011a; Sahu et al., 2011). In breast cancer 
cells, FoxA1 depletion leads to decreased ERα binding and attenuated estrogen-
dependent gene transcription (Carroll et al., 2005; Hurtado et al., 2011). Interestingly, in 
prostate cancer cells, FoxA1 plays a more diverse role and reprograms AR binding on a 
genome-wide scale: only a subset of AR-occupied enhancers is pioneered by FoxA1, and 
a significant proportion of new AR-binding events appear upon FoxA1 depletion (Sahu et 
al., 2011). Other pioneer factors reported for ERα are activating protein (AP)-2γ, GATA 
factors, and pre-B-cell leukemia homeobox 1 (PBX1) (Eeckhoute et al., 2007; Magnani 
et al., 2011a; Miranda-Carboni et al., 2011; Tan et al., 2011; Theodorou et al., 2013), 
whereas GATA-2 and ETS family members have been associated with AR binding (Chen 
et al., 2013; Chng et al., 2012; Massie et al., 2007; Wang et al., 2007; Wu et al., 2014; 
Yu et al., 2010). 
 
Early studies on the mouse mammary tumor virus promoter suggested that GR and PR 
are able to bind compact nucleosomal DNA, thus functioning as pioneer factors 
themselves (Perlmann and Wrange, 1988; Sun et al., 1983). However, genome-wide 
studies have revealed that GR binds predominantly to accessible chromatin (John et al., 
2008; John et al., 2011) and identified other proteins functioning as pioneer factors for 
GR, including FoxA1 (Sahu et al., 2011), AP1 (Biddie et al., 2011), and C/EBP 
(Grøntved et al., 2013). Nevertheless, a recent mapping of the PR cistrome and chromatin 
structure in breast cancer cells reported that functionally active PR-binding events reside 
in nucleosomal DNA and that ligand-induced PR binding initiates chromatin remodeling, 
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providing genome-wide evidence for PR functioning as a pioneer factor (Ballare et al., 
2013). AR has not been reported to bind nucleosomal DNA, but a significant subset of 
AR-binding events in prostate cancer cells is not affected by FoxA1 depletion (Sahu et 
al., 2011), suggesting involvement of other factors in creating the open chromatin 
conformation. Thus, although the functional importance of pioneer factors in steroid 
receptor signaling is well-established, our understanding of comprehensive mechanistic 
insights into the interplay of receptors, pioneer factors and chromatin modifications is 
still very limited.  
3.4 Tissue-specific functions of steroid receptors 
Steroid receptors facilitate specific transcriptional responses at different stages of 
development and in various cell types and tissues. Steroid hormones circulate in 
bloodstream, and are thus available for all tissues in the body. The first determinant for 
cell type- and tissue-specificity of hormone action is the expression of the cognate 
receptor. Transcript variants have been identified for all steroid receptors, and the 
different isoforms can potentially modulate tissue-specificity of responses. For example, 
PR-A isoform is essential for uterine and PR-B for mammary gland development in the 
mouse (Mulac-Jericevic et al., 2003; Mulac-Jericevic et al., 2000), but most human target 
tissues express the two isoforms at similar levels (Scarpin et al., 2009). GR expression 
levels are under the control of nine alternative untranslated first exons, and alternative 
splicing at the 3’ end of GR mRNA leads to three protein isoforms (Oakley and 
Cidlowski, 2011). Of the two estrogen receptors, both of which are expressed in many 
target tissues, ERβ often has repressive effect on ERα transcriptional activity in vivo, for 
example, in uterus (Weihua et al., 2000). Nevertheless, although protein isoforms can 
modulate steroid receptor-mediated responses, other mechanisms are needed to ensure 
full spectrum of their tissue-specific functions. 
 
A plethora of coregulatory proteins can contribute to tissue-specific transcriptional 
responses. Studies with tissue-selective steroid receptor modulators have demonstrated 
how differential expression patterns and isoform-selective interactions with steroid 
receptors can modulate transcriptional outcome (Smith and O'Malley, 2004). For 
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example, tamoxifen-bound ER recruits corepressors in mammary gland cells, but is able 
to stimulate gene expression in the uterus due to high SRC-1 expression levels (Shang 
and Brown, 2002). Genome-wide mapping of genomic loci associated with SRC proteins 
and ERα binding identified a subset of estradiol-regulated genes characterized by the 
presence of SRC-3, and not the other SRC family members, that correlated with 
tamoxifen-resistance and breast cancer prognosis (Zwart et al., 2011). An in vivo study 
utilizing a PR activity indicator mouse crossed with knockout mice for SRCs showed that 
the primary PR coactivators are SRC-3 in breast tissue and SRC-1 in uterus (Han et al., 
2006). Other cellular proteins are likely to contribute to tissue-specific transcriptional 
regulation as well, for example, a majority of nuclear envelope proteins capable of 
organizing intranuclear landscape and affecting nuclear functions exhibit tissue-restricted 
expression patterns (de Las Heras et al., 2013). 
 
The ligand, the receptor, and coregulators are mandatory for steroid hormone-mediated 
gene regulation, but they are not sufficient for determining the landscape of receptor 
occupancy and subsequent transcriptional outcome. Cell type-specific transcription factor 
binding is often associated with specific histone modifications (Barrera et al., 2008; 
Heintzman et al., 2009), DNA methylation status (Wiench et al., 2011a), and accessible 
chromatin (John et al., 2011; Tang et al., 2011). Genome-wide mapping of transcription 
factor cistromes has revealed that the distal regulatory elements define cell type-specific 
gene regulation in human and mouse (Heintzman et al., 2009; Shen et al., 2012). 
Interestingly, distinct enhancers also drive expression of common genes in different cell 
types (Kieffer-Kwon et al., 2013) and the ENCODE project revealed a vast diversity of 
enhancers in the human genome (The ENCODE Project Consortium, 2012). However, 
the determinants ensuring favorable chromatin structure and the factors governing 
receptor recruitment to these specific enhancer sites are still elusive, despite the 
technological advancements in mapping the chromatin structure, histone modifications, 
and transcription factor occupancy. 
 
Recent genome-wide studies have suggested that pioneer factors might play a role in the 
tissue-specific receptor binding (Eeckhoute et al., 2009) and have proposed mechanisms, 
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such as covalent histone modifications (Lupien et al., 2008) and DNA hypomethylation, 
governing pioneer factor binding to tissue-specific loci (Serandour et al., 2011; Xu et al., 
2007), and cohesin stabilizing tissue-specific protein-DNA complexes (Faure et al., 
2012). Cell type-specific ERα binding was reported to associate with differential gene 
regulation in MCF-7 breast cancer cells and U2-OS osteosarcoma cells ectopically 
expressing ER (Krum et al., 2008) as well as in breast and endometrial cancer cell lines 
(Gertz et al., 2013). Interestingly, FoxA1 has been shown to define cell type-specific 
binding of AR and GR to chromatin even between two prostate cancer cell lines, namely, 
AR in LNCaP-1F5 cells and GR in VCaP cells (Sahu et al., 2013). Moreover, FoxA1 
determines lineage-specific ER and AR binding in breast and prostate cancer cells, 
respectively (Lupien et al., 2008) and differential ER and AR function in hepatocytes (Li 
et al., 2012b). 
 
Most steroid receptor cistromes have thus far been analyzed in few well-characterized 
cancer cell lines, and the tissue-specific cistromes representing physiological conditions 
are very limited. Moreover, many ChIP-seq studies from intact tissues or cancer cell lines 
that have suggested that pioneer factors dictate cell type-specific cistromes, have reported 
only enriched cis-elements within the receptor-bound regions, not taking into account 
whether or not these elements are actually occupied by the cognate factor, such as the 
recent PR cistromes suggesting differential cis-element enrichment around PR-binding 
events in the mammary gland and uterus (Lain et al., 2013; Rubel et al., 2012; Yin et al., 
2012). Table 2 summarizes the pioneer factors reported for steroid receptors in various 
cell types thus far, but a comprehensive view of the ways by which pioneer factors 
contribute to tissue-specific transcriptional outcome is still lacking. Thus, in vivo studies 
under physiological conditions are of prime importance, which has been one of the 
primary scopes of this thesis.   
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Table 2. Summary of pioneer factors associated to steroid receptor function in different cell 
types. Only validated studies reporting putative pioneer factor occupancy at shared sites with 
steroid receptors are listed. 
 
Receptor Tissue of origin Cell type Pioneer factor References 
ERα  Mammary gland 
 
MCF-7 and T-47D breast 
cancer cell lines 
FoxA1 Carroll et al., 2005 
Lupien et al., 2008 
Hurtado et al., 2011 
Ross-Innes et al., 2012 
Theodorou et al., 2013 
Gertz et al., 2013 
MCF-7  PBX1 Magnani et al., 2011 
MCF-7  AP-2γ Tan et al., 2011 
MCF-7 and T-47D breast 
cancer cell lines 
GATA-3 Eeckhoute et al., 2007 
Theodorou et al., 2013 
Gertz et al., 2013 
Uterus ECC-1 cancer cell line ETV4 Gertz et al., 2013 
Bone U2OS-ER osteosarcoma cell 
line 
GATA-4 Miranda-Carboni et 
al., 2011 
Liver Hepatocyte from liver tissue FoxA1 Li et al., 2012b 
AR Prostate 
 
LNCaP, LNCaP-1F5, VCaP 
prostate cancer cell lines  
FoxA1 Lupien et al., 2008 
Wang et al., 2009 
Sahu et al., 2011 
Sahu et al., 2013 
Wang et al., 2011 
LNCaP  GATA-2 Wang et al., 2007 Wu et al., 2014 
LNCaP  ETS1 Massie et al., 2011 
LNCaP, VCaP lines, mouse 
prostate ERG 
Yu et al., 2010 
Chng et al., 2012 
Chen et al., 2013 
Mammary gland MDA-MB-453 ER-AR+ 
molecular apocrine breast 
cancer cell line 
FoxA1 Robinson et al., 2011a 
Ni et al., 2011 
Liver Hepatocyte from mouse tissue FoxA1 Li et al., 2012b 
GR Prostate LNCaP-1F5, VCaP prostate 
cancer cell lines 
FoxA1 Sahu et al., 2011 
Sahu et al., 2013 
Mammary gland 3134 murine mammary 
epithelial cells 
AP1 Biddie et al., 2011 
Liver Hepatocyte from mouse tissue C/EBP Grøntved et al., 2013 
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4.  Androgen receptor  
4.1 AR and its regulation 
Androgens regulate cellular functions through AR and the AR gene is expressed in 
various tissues and cell types, including Leydig and Sertoli cells in testis, both epithelial 
and stromal compartments of accessory sex organs, such as prostate and seminal vesicles, 
and many cell types in non-reproductive tissues, such as skeletal muscle, bone, fat, and 
skin (De Gendt and Verhoeven, 2012). Expression of the human AR is governed by a 
TATA-less promoter (Faber et al., 1991; Tilley et al., 1990), and many transcription 
factors have been implicated in AR expression, including CREB, Myc, c-Jun, Sp1, 
Foxo3a, and LEF1 (Shiota et al., 2011). Recently, it was reported that AR represses its 
own transcription by recruiting LSD1 to an enhancer at second intron of AR (Cai et al., 
2011). Normal splicing of AR exons 1–8 results in 10.6-kb mRNA species with a 2.7-kb 
open reading frame. A naturally occurring splice variant for AR, termed AR45, is 
produced from an alternative first exon and yields a 45-kDa receptor isoform in which the 
entire NTD is replaced by seven novel amino acids (Ahrens-Fath et al., 2005). 
Ectopically expressed AR45 is a negative regulator of AR signaling, but its functional 
significance in vivo remains elusive (Dehm and Tindall, 2011).   
 
Cloning of the AR cDNA and chromosomal localization of the AR gene to Xq11-12 
(Chang et al., 1988; Lubahn et al., 1988) initiated the molecular characterization of AR 
protein function and mapping of variations in the AR gene and its expression (Brinkmann 
et al., 1989). Subsequent studies have shed light into the molecular pathogenesis of 
clinical conditions, such as prostate cancer and androgen insensitivity syndrome (AIS), 
although the connection of these disorders to androgens was established already more 
than 50 years ago. Mutations in the AR gene disrupting the functional domains of the 
protein lead to AIS with characteristics of normal serum androgen levels but subnormal 
signs of androgen action. The severity of the symptoms reflects the defects in AR protein, 
and most reported mutations affect the LBD of AR (Jääskeläinen, 2012). Androgens 
promote proliferation of normal and malignant prostatic cells, and androgen deprivation 
therapy is often used to inhibit growth of prostate tumors. Advanced stages of prostate 
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cancer are characterized by AR-dependent but castration-resistant tumor growth that is 
often achieved through AR mutations or overexpression (Knudsen and Kelly, 2011). AR 
splice variants with truncated carboxyl terminus found in prostate cancer cells generate a 
ligand-independent receptor (Dehm et al., 2008; Guo et al., 2009; Hu et al., 2009; Sun et 
al., 2010). Recently, AR gene rearrangements modeled using transcription activator-like 
effector nuclease (TALEN) genome engineering showed that constitutionally active, 
truncated AR is able to drive transcriptional program similar to that of the full-length 
receptor, highlighting a mechanism for androgen-independent growth of castration-
resistant tumors (Nyquist et al., 2013).  
4.2 Structural and functional domains of androgen receptor 
The modular structure of AR protein comprises the typical functional domains of steroid 
receptors. NTD of AR is encoded by exon 1 of AR, exons 2 and 3 encode the first and 
second zinc fingers in the DBD, respectively, and exons 4–8 are responsible for the hinge 
region and the carboxyl-terminal LBD (Figure 5A). AR is subject to PTMs that alter its 
transcriptional activity and contribute to the stability of the protein (Gioeli and Paschal, 
2012). So far, five different modifications and 23 modifiable residues have been reported 
(Figure 5B).  
 
 
Figure 5. Eight exons of the AR gene (A) encode four functional domains of the AR protein (B). 
Amino acid residues with reported post-translational modification are indicated. Adapted and 
reprinted from Gioeli & Paschal, Post-translational modification of the androgen receptor, 
Molecular and Cellular Endocrinology 352:70–78, 2012, with permission from Elsevier 
(copyright 2012). 
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NTD is the least conserved of the AR functional domains, but it harbors conserved areas 
responsible for specific functions, namely, the ligand-dependent interaction with LBD 
(Ikonen et al., 1997) and the AF-1 (Palvimo et al., 1993). General mechanism of nuclear 
receptor activation by ligand binding induces repositioning of helix 12 and forming a 
hydrophobic cleft that constitutes AF-2. A unique feature of AF-2 within the AR LBD is 
that it predominantly interacts with the FxxLF motif in the AR NTD and not with 
transcriptional coactivators as in other steroid receptors (Dubbink et al., 2004; van de 
Wijngaart et al., 2012). Thus, AF-1 is the primary site for coactivator binding in AR and, 
unlike other steroid receptors, constitutively active AR lacking LBD retains 
transcriptional activity nearly equal to that of the full-length receptor (Alen et al., 1999; 
Bevan et al., 1999). NTD also contains majority of the phosphorylation sites within AR. 
Phosphorylation is the most abundant of the AR PTMs, and it affects protein-protein 
interactions in the proximity of the phosphorylated site, modulating interaction with 
coregulators and AR transcriptional activity (Gioeli and Paschal, 2012). Another PTM 
targeting the NTD is sumoylation, i.e., conjugation of small ubiquitin-like modifiers 
(SUMO) to lysine residues. Mutation analyses have revealed that sumoylation of AR 
primarily at lysine 386 attenuates AR transcriptional activity (Kaikkonen et al., 2009; 
Poukka et al., 2000). NTD of human AR also harbors polymorphic polyglutamine and 
polyglycine tracts of varying length. The length of polyglutamine tract alters AR 
transcriptional activity (Mhatre et al., 1993), and it is likely to play a role in pathogenesis 
of prostate cancer (Robins, 2012). 
 
Highly conserved AR DBD contains two zinc fingers, each possessing four cysteines 
tetrahedrally coordinated to a Zn2+ ion. The amino acids in the α-helix of the first zinc 
finger (P-box) recognize nucleotides in the major groove of the DNA-binding element, 
whereas D-box within the second zinc finger forms the dimerization interface (Luisi et 
al., 1991; Shaffer et al., 2004) (Figure 6). In addition to the palindromic ARE/GREs 
recognized by all NR3C family steroid receptors, AR binds to selective AREs that are not 
recognized by GR, as discussed in Chapter 3.2 (Denayer et al., 2010). Comparison of 
crystal structures of AR and GR DBDs revealed that the spatial positioning of the four 
amino acid residues that are different in the dimerization interfaces of AR and GR DBDs 
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allow AR to make stronger DBD-DBD contacts (Shaffer et al., 2004), potentially 
contributing to AR binding to selective AREs (Helsen et al., 2012). Biochemical analyses 
have implicated also the first 12 amino acids of the hinge region, the so-called carboxyl-
terminal extension, in selective AR binding (Schoenmakers et al., 1999). Interestingly, 
lysines within the carboxyl-terminal extension are the only acetylation and methylation 
sites reported for AR (Fu et al., 2000; Gaughan et al., 2002; Gaughan et al., 2011; Ko et 
al., 2011). These PTMs enhance LBD-NTD interaction and transcriptional activation of 
AR, whereas serine phosphorylation in the hinge region increases its nuclear export 
(Gioeli and Paschal, 2012). 
 
Figure 6. A. Schematic presentation of AR DBD and carboxyl-terminal extension (CTE). B. 
Crystal structure of the AR DBD dimer bound to a selective ARE. Numbers 1–6 indicate the 
nucleotides in the first hexamer and 10–15 in the second hexamer. Reprinted from Shaffer et al., 
Structural basis of androgen receptor binding to selective androgen response elements. PNAS 
101:4758–4763, 2004. Copyright (2004) National Academy of Sciences, U.S.A. 
 
4.3 Androgen receptor-mediated gene regulation 
Androgen-induced dissociation from the heat shock complex, receptor dimerization and 
translocation to nucleus initiate AR-dependent transcriptional regulation. The bipartite 
nuclear localization signal of AR involves two clusters of amino acids located in the 
second zinc finger of the DBD and the hinge region (Figure 6) (Zhou et al., 1994), and its 
interaction with importin-α facilitates AR translocation to the nucleus upon ligand 
binding (Cutress et al., 2008). Early ChIP studies at regulatory elements of androgen-
induced genes in the kallikrein cluster characterized dynamic assembly of agonist-
induced transcription complex with AR, coactivators, such as p160 and CBP/p300 
proteins, and RNA polymerase II (Kang et al., 2004; Shang et al., 2002). AR-coactivator 
complex occupancy gradually increases peaking at 16 h after androgen-treatment, and 
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both chromatin looping and polymerase tracking were identified as a mechanism for 
enhancer-promoter interaction within the prostate-specific antigen (PSA, also known as 
kallikrein-related peptidase 3) gene (Wang et al., 2005). Looping has also been reported 
for the regulatory regions of other androgen-induced genes, such as TMPRSS2 (Wang et 
al., 2007), FKBP5 (Makkonen et al., 2009), and UBE2C (Chen et al., 2011). According 
to the looping model, the mediator complex facilitates the long-range communications 
(Malik and Roeder, 2010), and MED12 was reported to mediate the enhancer-promoter 
interaction in an androgen-induced fashion (Wang et al., 2011).  
 
The first chromosome- and genome-wide maps of AR binding using ChIP-on-chip 
technology revealed the distal enhancers as the primary AR loading sites and identified 
several collaborating transcription factors, namely GATA-2, FoxA1, and ETS1, co-
occupying these sites (Jia et al., 2008; Lupien et al., 2008; Massie et al., 2007; Wang et 
al., 2007). Subsequent high-resolution cistromes revealed that the genomic landscape of 
AR binding encompasses thousands of binding events (Yu et al., 2010), characterized the 
functional relationship of AR and FoxA1 with FoxA1 having both pioneering and 
repressive effects on AR binding (Sahu et al., 2011; Wang et al., 2011) and identified 
distinct chromatin modification, namely H3K4me2, marking active enhancers prior to 
AR recruitment (He et al., 2010) (Figure 7). Gene expression profiling studies have 
reported hundreds of androgen up- and down-regulated transcripts and identified multiple 
cellular pathways, such as anabolic metabolism, as androgen targets (Jin et al., 2013; 
Massie et al., 2011). Differential recruitment of coregulators directs transcriptional signal 
to local chromatin conformation, and over 200 coregulators implicated in AR function 
give rise to the diversity of responses and integration of signals from various cellular 
pathways (Heemers and Tindall, 2007; van de Wijngaart et al., 2012).  
 
The coactivators involved in AR-dependent gene activation include chromatin 
remodelers, such as BAF57, histone acetyltransferases, such as SRC-1, and histone 
methyltransferases, such as SET9 (Bevan et al., 1999; Gaughan et al., 2011; Link et al., 
2005). As discussed in Chapter 2.3, histone acetylation is associated with 
transcriptionally active enhancers, whereas histone methylation is involved in both gene 
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activation through methylation of H3K4 and gene repression through methylation of 
H3K9 and H3K27. Many methyltransferases and demethylases have been associated with 
AR-dependent gene activation and/or repression, such as LSD1 that is able to 
demethylate both H3K4 and H3K9 (Cai et al., 2011; Cai et al., 2013; Metzger et al., 
2005). However, determinants of LSD1 function and subsequent gene activation or 
repression are largely elusive. Furthermore, both FoxA1-pioneered and FoxA1-
independent AR-binding events are characterized by H3K4me2 marks (He et al., 2010; 
He et al., 2012; Sahu et al., 2011), which raises an intriguing question about the 
mechanistic interplay between histone methylation and pioneer factors for the provision 
of chromatin environment favorable to AR binding. 
 
 
Figure 7. Characteristic events of androgen-dependent gene activation. FoxA1 represents a 
pioneer factor that primes chromatin for AR binding. Demethylase LSD1 and acetylases SRC-2 
and p300 are examples of coregulators recruited to enhancers by AR, but other factors not shown 
in the figure are also involved in functional transcriptional complex. The spheres representing 
histone modifications are color-coded as follows: blue for repressive marks such as H3K9me3 
and H3K27me3, and pink and green for activating marks H3K4me and H3K27ac, respectively. 
 
The mechanisms of gene repression are likely to involve both protein-protein interactions 
as well as direct AR binding to regulatory elements of repressed genes and recruitment of 
corepressors such as NCoR and SMRT, resulting in histone deacetylation (Grosse et al., 
2012). Both androgen up- and down-regulated genes are associated with AR- and FoxA1-
binding sites (Sahu et al., 2011), but recruitment of corepressors HDAC1, 2, 3 and EZH2 
was reported to occur specifically to a subset of AR-binding loci shared with ERG (Chng 
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et al., 2012). Moreover, a direct repressive mechanism has been described with AR-
dependent recruitment of LSD1 in repressing AR expression (Cai et al., 2011) and EZH2-
mediated H3K27 trimethylation for number of repressed genes (Zhao et al., 2012).  
4.4 Androgen receptor ligands and exogenous modulators  
The major physiological androgens are testosterone and 5α-dihydrotestosterone (DHT). 
Testosterone is synthetized from cholesterol in testis under the control of hypothalamic-
pituitary axis. Hypothalamus secretes gonadotropin-releasing hormone that stimulates 
production of luteinizing hormone in anterior pituitary that, in turn, promotes testosterone 
synthesis in the Leydig cells of testis. Negative feedback-loop regulates testosterone 
synthesis, in that low circulating steroid levels release the hypothalamus and pituitary 
from feedback inhibition. Other physiological sources of androgens include the ovaries in 
females and the adrenal cortex in both genders. In many target tissues, such as prostate 
and skin, 5α-reductase catalyzes conversion of testosterone to a more potent androgen, 
DHT, that has 5-10 times higher affinity for AR compared to that of testosterone. In some 
tissues, testosterone can be also aromatized to estradiol.  
 
Androgen deprivation therapy is used to suppress transcriptional activity of AR in 
prostate cancer patients. Androgen deprivation can be achieved by decreasing 
testosterone levels by surgical or pharmacological castration, or by inhibiting AR 
function in the target cells by antagonistic compounds that compete with testosterone or 
DHT for AR binding. The first antagonist developed for AR, cyproterone acetate, has a 
steroidal structure, and it also has agonistic effects on AR function (Wilding et al., 1989). 
ChIP-seq profiling of AR cistromes in prostate cancer cells demonstrated that AR-
binding patterns are very similar in response to DHT and cyproterone acetate (Sahu et al., 
2013). The non-steroidal antiandrogens flutamide and bicalutamide can also exert 
agonistic effects in the presence of high cellular AR content (Chen et al., 2004). Novel 
compounds targeting the AR pathway are abiraterone acetate, a CYP17 inhibitor that 
blocks androgen production (Attard et al., 2008), and the second generation antiandrogen 
enzalutamide that binds to AR with higher affinity than bicalutamide and inhibits 
receptor translocation to the nucleus (Tran et al., 2009).  
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Distinct androgen effects in various tissues have prompted the search for selective 
androgen receptor modulators. Activation of the AR pathway in muscle and bone would 
be beneficial in conditions involving loss of muscle mass, such as age-related frailty 
syndrome and cachexia, but androgens also play a role in the development of prostate 
hyperplasia and carcinoma. Binding of androgen receptor modulators to the ligand-
binding pocket of the AR LBD may cause subtle differences in receptor conformation 
when compared to the DHT-activated AR, thus potentially leading to differential 
interaction with coregulators, other transcription factors, and AREs (Haendler and Cleve, 
2012). This is supported by conformational differences in crystal structures of the AR 
LBD complexed with different ligands, namely cyproterone acetate, bicalutamide, 
LGD2226, and N-aryl-hydroxybicyclohydantoin-based compounds (Bohl et al., 2005; 
Bohl et al., 2007; Sun et al., 2006; Wang et al., 2006). Several compounds with varying 
androgenic and anabolic effects have entered clinical trials, but potential side effects as 
well as in vivo efficacy in humans need to be assessed (Haendler and Cleve, 2012). 
 
Natural compounds or industrial chemicals with abilities to modulate nuclear receptor 
action, the so-called endocrine disruptors, have recently gathered interest due to their 
possible roles in risk and prevention of hormone-dependent disorders (Diamanti-
Kandarakis et al., 2009). For instance, bisphenol A, a plasticizer used in polycarbonate 
products, has been associated with adverse effects, such as altered behavior and asthma in 
children (Rochester, 2013). Although the extent of health risks associated with bisphenol 
A exposure are still under debate, increased public awareness and scientific evidence 
have resulted in banning of polycarbonate plastics in baby bottles in many countries. 
Several endocrine disruptors show antiandrogenic properties, including fungicides 
vinclozolin and procymidone, and plasticizers bisphenol A and phthalates (Luccio-
Camelo and Prins, 2011). Some environmental compounds, such as soy phytoestrogens, 
have been associated with attenuated prostate cancer risk in several cohort and case-
controlled studies (Jian, 2009; Yan and Spitznagel, 2009). Better understanding of 
molecular mechanisms elicited by endocrine modulators is needed to correctly assess 
their potential health risks or benefits. Especially in vivo studies are warranted to 
complement epidemiological risk analysis and in vitro cell culture-based assays.  
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5.  Androgen signaling in vivo 
5.1 Effects of androgens on male sexual function 
Sex hormones are not crucial to the life of an individual, but they are absolutely 
necessary for the reproduction and survival of metazoan species. The essential role that 
androgens play in male physiology is demonstrated by the feminine phenotypes of 
46,XY-males with AIS, characterized by undescended testis producing testosterone but 
feminine external genitalia and secondary sexual features (Jääskeläinen, 2012). Genital 
ridges in mammalian embryo are capable of differentiating into testes or ovaries. 
Importantly, male sex determination depends on the expression of the Y-chromosomal 
sex-determining region Y (SRY) gene that induces differentiation of Sertoli cells and 
formation of testis. Testosterone and DHT are responsible for masculinization of the 
embryo by directing the development of genital organs in concert with other cellular 
signaling pathways (Wilhelm and Koopman, 2006). Testosterone production by murine 
fetal Leydig cells is luteinizing hormone-independent (Zhang et al., 2001), but in human 
chorionic gonadotropin is required for initiation of testosterone production 
(O’Shaughnessy et al., 2006).  
 
Starting from puberty, androgens promote the development of male secondary sexual 
characteristics, such as growth of larynx, resulting in deeper voice, and male pattern hair 
growth. Likewise, maturation and function of reproductive organs is highly androgen-
dependent. Testosterone is an essential regulator of spermatogenesis through AR 
expression in Sertoli cells and peritubular myoid cells – but not in germ cells–, as 
elucidated by cell-type specific AR knockout (ARKO) mouse models (De Gendt et al., 
2004; Holdcraft and Braun, 2004; Tsai et al., 2006; Welsh et al., 2009). Epididymis is the 
organ where sperm maturation takes place, and highly androgen-responsive accessory sex 
glands, seminal vesicle and prostate, secrete fluids and compounds that contribute to 
sperm functionality. In these tissues, AR is expressed both in stromal and epithelial 
compartments, and it can thus elicit various effects on tissue morphology and secretory 
functions (De Gendt and Verhoeven, 2012). Epididymis is a tubule with four distinct 
segments responding differently to castration and testosterone-treatment in terms of 
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cellular proliferation and gene expression patterns (Hamzeh and Robaire, 2009; Sipilä et 
al., 2006). In prostate, AR ablation in stromal cells results in defective epithelial 
proliferation (Yu et al., 2011), whereas epithelial cell-selective ARKO mice display 
hyperproliferation and poor differentiation of prostatic epithelium (Simanainen et al., 
2007; Wu et al., 2007). 
5.2 Androgen action in non-reproductive tissues 
Androgens have anabolic actions in many non-reproductive tissues, including bone, fat, 
and skeletal muscle. Androgens stimulate both linear bone growth and skeletal maturity, 
finally leading to closure of epiphyseal plates and termination of growth. Testosterone 
affects bone both by direct AR activation and through ER after testosterone 
aromatization. Furthermore, growth hormone and insulin-like growth factor 1 contribute 
to growth, as both sex steroids and growth hormone markedly increase during puberty, 
and their actions are mutually amplified in the control of growth, increase in muscle 
mass, and mineralization of the skeleton (Callewaert et al., 2010). Osteoblast-selective 
ARKO mouse demonstrated that androgens keep promoting bone health throughout the 
life by regulating bone resorption (Notini et al., 2007). In muscle, testosterone increases 
muscle size and strength in both young and elder men (Bhasin et al., 1996; Bhasin et al., 
2005). Testosterone increases protein synthesis in skeletal muscle leading to hypertrophy 
(Ferrando et al., 1998), but it also induces proliferation of skeletal muscle progenitor cells 
(Sinha-Hikim et al., 2003). Myocyte-selective ARKO models have highlighted distinct 
responses to AR ablation between different muscle types, in that the weight of highly 
androgen-responsive levator ani but not the limb muscles was decreased by the ablation 
(Chambon et al., 2010; Ophoff et al., 2009). Better understanding of testosterone actions 
in bone and muscle would benefit in the quest for developing selective AR modulators 
for clinical use. 
 
Also other tissues, such as liver and kidney, are androgen-responsive, and exhibit sexual 
dimorphism in their physiology and under pathophysiological conditions (Chang et al., 
2013). Hepatocytes of both genders express AR, and AR expression is increased in liver 
carcinoma (Eagon et al., 1991). The incidence of hepatocellular carcinoma is lower in 
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women than men (Ferlay et al., 2010), and a recent in vivo ChIP-seq study demonstrated 
that FoxA pioneer factors mediate both the protective effects of ER and the deleterious 
effects of AR to the pathogenesis of liver carcinoma in mice (Li et al., 2012b). In rodent 
kidneys, AR regulates many well-studied target genes, and AR expression has been 
located to proximal tubules of the renal cortex by studies on the expression of kidney 
androgen-regulated protein (Kap) (Meseguer and Catterall, 1990) and ornithine 
decarboxylase 1 (Odc1) (Crozat et al., 1992). Androgens promote cellular hypertrophy 
and polyamine synthesis in murine kidney (Catterall et al., 1986; Tovar et al., 1995), and 
testosterone-induced AR has been implicated in the pathogenesis of hypertension in rats 
(Reckelhoff et al., 2000). However, the role that androgens play in human kidney remains 
elusive. Furthermore, although compilation of physiological effects of androgens are well 
known in several target tissues, the molecular mechanisms of these effects are just 
beginning to emerge, and further studies with state-of-the-art approaches are required. 
5.3 Androgen-related diseases 
Androgen insensitivity syndrome (AIS) and Kennedy’s disease (spinal-bulbar muscular 
atrophy, SBMA) are rare conditions inherited in an X-linked recessive manner. Both are 
caused by mutations in AR; AIS by missense or nonsense mutations mostly in the LBD 
resulting in impairment or complete loss-of-function of AR, and SBMA by expansion of 
polymorphic CAG repeat in the NTD beyond 40 repeats, leading to AR protein with 
neuronal toxicity (Matsumoto et al., 2013). Currently, there is no effective treatment for 
AIS or SBMA. AR has been implicated in many cancers (Chang et al., 2013), and it can 
serve as a molecular mechanism to bypass ER signaling in breast cancer (Ni et al., 2011; 
Robinson et al., 2011a). However, prostate cancer is by far the most common AR-related 
disease, and AR signaling plays a significant role in all stages of this disease. 
 
Prostate cancer is the second-most commonly diagnosed cancer worldwide among men, 
with almost 900,000 new cases every year (Ferlay et al., 2010). Its advanced forms are 
associated with high mortality rates, and at present lack curative treatment. Androgen 
signaling is essential not only for normal prostate development, but also for the growth of 
prostatic malignancies (Lonergan and Tindall, 2011). Prostate cancer is a heterogeneous 
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disease often characterized by the loss of NKX3-1, PTEN, and retinoblastoma genes 
(Shen and Abate-Shen, 2010). The most common genomic rearrangement found in about 
a half of prostate cancers is the TMPRSS2:ERG fusion, resulting in androgenic control of 
the expression of oncogenic ETS transcription factors (Tomlins et al., 2005). Moreover, 
exome sequencing of prostatic tumors have identified recurrent mutations in SPOP, 
FOXA1, and MED12, as well as in genes for several chromatin and histone-modifying 
enzymes (Barbieri et al., 2012; Grasso et al., 2012), and a recent study identified a 
prostate cancer predisposition allele associated with a stronger binding of the HOXB13 
transcription factor resulting in altered RFX6 expression (Huang et al., 2014).  
 
Androgen signaling is central to all stages of prostate cancer, and androgen deprivation 
therapy is used to suppress tumor growth. In castration-resistant prostate cancer (CRPC), 
AR signaling is reactivated through multiple mechanisms, such as AR deregulation, 
intracrine androgen synthesis, AR mutations and alternative splicing, and alterations in 
PTMs and coregulatory pathways (Knudsen and Kelly, 2011). Genome-wide AR profiles 
in CRPC cell lines have shown a set of binding loci occupied by AR in the absence of 
androgens (Decker et al., 2012; Wang et al., 2009). The first ChIP-seq study reporting 
AR-binding events in clinical CRPC tissues showed only a moderate overlap with AR 
cistromes present in prostate cancer cell lines, demonstrating the heterogeneity of the 
disease (Sharma et al., 2013). The role of FoxA1 in AR signaling has been extensively 
studied in various prostate cancer cells over the past decade (Augello et al., 2011). 
Importantly, FoxA1 protein expression in prostate cancer tissue was identified as a poor 
prognostic marker for disease progression (Sahu et al., 2011; Robinson et al., 2013). ETS 
transcription factors have also been intensively studied, in particular after the 
identification of the TMPRSS2:ERG fusion protein, and an integrated repressive pathway 
involving AR, ETS factors and polycomb protein EZH2-mediated histone methylation 
has been described (Yu et al., 2010; Zhao et al., 2012). Recent transgenic mouse models 
underline the role of another ETS factor involved in gene fusions, ETV1, in modulating 
AR signaling (Baena et al., 2013; Chen et al., 2013). At present, prostate specific antigen 
(PSA) is the only widely-used biomarker for prostate cancer progression, but the novel 
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findings are anticipated to provide a better classification of prostatic tumors according to 
their molecular subtypes in the years to come. 
5.4 Mouse models to study AR 
Various in vivo approaches have contributed to our understanding of androgen-regulated 
AR action. Castration allows for observing the effects of androgen withdrawal, and 
subsequent ligand-treatment can be used to modulate the AR pathway. Mice do not 
express the enzymatic pathway to synthesize androgens in the adrenals, and castration of 
male mice leads to complete androgen ablation (van Weerden et al., 1992). A mouse 
model with a phenotype closely resembling AIS was reported in 1970, and this testicular 
feminization (Tfm) mouse line was used to delineate androgen action in the development 
of male phenotype (Lyon and Hawkes, 1970) and in sexual dimorphism of extragenital 
tissues (Bardin and Catterall, 1981). Subsequently, transgenic full ARKO mice have been 
developed, and similar to Tfm males, ARKO mice display a female appearance with 
small intra-abdominally located testes as their only internal reproductive organs 
(Matsumoto et al., 2003; Yeh et al., 2002). Furthermore, cell-type specific ARKO mouse 
models have provided more detailed mechanistic insights into AR function in different 
cells and organs, as described in Chapters 5.1 and 5.2.  
 
In addition to knockout models, knock-in approaches have been used to study AR action. 
Knock-in models to study prostate cancer and SBMA, generated by swapping the murine 
AR NTD to its human counterpart and introducing polyglutamine tracts of varying 
lengths (Albertelli et al., 2006; Robins, 2012), reported neuromuscular pathology in 
males with the longest CAG repeat of 113 triplets (Yu et al., 2006). Short polyglutamine 
tract of 12 repeats, on the other hand, was associated to earlier development of prostate 
cancer when these knock-in mice were crossed with the TRAMP prostate cancer mouse 
model (Albertelli et al., 2008). In a different knock-in approach, swapping of the second 
zinc finger of AR to that of GR created a chimeric receptor capable of binding to classical 
but not selective AREs (Schauwaers et al., 2007; Schoenmakers et al., 1999). The 
transgenic males with this chimeric AR, termed specificity affecting AR knock-in 
(SPARKI), have smaller reproductive organs than their wild-type littermates (Schauwaers 
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et al., 2007). SPARKI males are subfertile, owing to the impaired sperm maturation in 
the epididymis (Kerkhofs et al., 2012). Comparison of genome-wide binding profiles for 
SPARKI and wild-type AR in vivo was one of the aims of this thesis. 
Transgenic mice expressing a reporter gene driven by hormone-responsive enhancers can 
be used to elucidate nuclear receptor function in live animals in vivo (Maggi and Ciana, 
2005). A few models reporting for AR action in prostate have been described with the 
reporter gene expression being driven by human PSA or KLK2 promoters (Iyer et al., 
2005; Lyons et al., 2006; Xie et al., 2004). AR activity indicator mouse, however, 
harbors a modified AR with the GAL4 DBD driving LacZ expression (Ye et al., 2005). 
Cross-breeding of this mouse line with knockout models for AR coregulators showed that 
AR activity in the testis is decreased by the loss of SRC-2, whereas ablation of SRC-1 
surprisingly increases AR activity (Ye et al., 2005). Reporter mice are promising tools for 
elucidating spatio-temporal patterns of AR activity in vivo in a noninvasive fashion, but 
the full extent of their potential remains to be established. Several transgenic mouse 
models have also been developed for studying prostate cancer, mostly with targeted 
expression of oncogenes or disruption of tumor suppressor genes (Wu et al., 2013).  
 
The AR signaling pathway is highly conserved in mammals. Within AR proteins, DBD 
and LBD are identical in human and mouse, the hinge region harbors few different amino 
acids, and the NTDs differ by 15% in protein sequence (Robins, 2012). In general, 
conservation of transcription factor cistromes has been reported for mouse and human 
(Hemberg and Kreiman, 2011), although huge plasticity in the distal regulatory elements 
also results in different binding patterns and regulatory pathways among species (The 
ENCODE Project Consortium, 2012; McLean et al., 2011; Odom et al., 2007). 
Nevertheless, many functional targets and DNA binding preferences are conserved 
(Schmidt et al., 2010), and in many regards, the mouse is an optimal model system with 
sophisticated genome manipulating tools and vast amount of data available on mouse 
strains, mutant phenotypes, and disease models (Keane et al., 2011). In conclusion, both 
wild-type mice and transgenic mouse models provide valuable information about 
physiological processes including androgen action and gene regulation. 
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AIMS OF THE STUDY 
The purpose of this study was to elucidate molecular mechanisms of AR action under 
physiological conditions in vivo. Wild-type mice as well as two transgenic mouse models 
were studied using modern approaches, including in vivo imaging, gene expression 
profiling, and ChIP-sequencing. The specific aims were the following: 
 
 
Aim 1  To develop and characterize a transgenic androgen reporter mouse line. 
 
Aim 2 To study the effects of the phytoestrogenic isoflavonoid genistein on AR 
signaling in vivo. 
 
Aim 3 To elucidate AR cistromes and androgen-induced transcription programs 
in three androgen-responsive tissues – prostate, kidney, and epididymis – 
and to delineate the mechanisms of tissue-specific gene expression. 
 
Aim 4 To examine the significance of AR DNA-binding domain in and of itself 
in determining the rules for in vivo chromatin binding in two androgen-
responsive tissues, epididymis and prostate, by utilizing the SPARKI 
transgenic mouse line. 
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MATERIALS AND METHODS 
1. Mouse models and treatments 
1.1 Transgenic mouse models 
To produce the androgen reporter mouse line, Slp-HRE2-TATA-Luc construct (Verrijdt 
et al., 2000), a kind gift from Dr. G. Verrijdt (University of Leuven, Belgium), containing 
four AREs (Slp-HRE2) of the mouse Slp gene (Adler et al., 1993), thymidine kinase 
minimal promoter, and TATA-box driving the expression of the luciferase reporter gene 
was used. The 3-kb matrix attachment region (MAR) insulator sequence from the chicken 
lysozyme gene (Phi-Van et al., 1990), kindly provided by Professor W. H. Strätling 
(University of Hamburg, Hamburg, Germany), was subcloned to the 5’ and 3′ ends of 
Slp-HRE2-TATA-Luc to generate the reporter construct pGEM3Z-Slp-HRE2-TATA-
Luc-5′MAR-3′MAR. The final construct was verified by restriction enzyme digestions 
and DNA sequencing. The pGEM3Z-Slp-HRE2-TATA-Luc-5′MAR-3′MAR construct 
was digested with SmaI to remove plasmid DNA. The 8.4-kb DNA fragment was gel-
purified and injected into zygotes of FVB/N mice using standard pronuclear injection 
techniques, and the embryos were transferred into pseudopregnant females. Genotyping 
was performed by PCR with primers detecting the reporter construct (communication I). 
 
SPARKI transgenic mouse model was designed in the group of Professor Frank 
Claessens (University of Leuven, Leuven, Belgium) and produced in the laboratory of Dr. 
Johan Auwerx (Institute of Genetics and Molecular and Cellular Biology, Strassbourg, 
France). The details of the procedure have been previously published (Schauwaers et al., 
2007). In short, the second zinc finger of the AR BDB was swapped to the respective part 
of the GR DBD by creating a targeting vector in which exon 3 of Ar was replaced with 
exon 4 of Gr. Morula aggregation of the targeted ES cell clone with C57BL/6 blastocysts 
produced a chimeric male mouse. Transgenic female offspring from chimeric breeding 
was crossed with a C57BL/6 CMV-CRE male to achieve male offspring with a mutant 
AR allele without the neomycin cassette. The mice were tested for the presence of wild-
type or mutated AR by PCR analysis. 
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1.2 Mice and hormonal treatments 
All the experiments were carried out using 8–12-week-old male and female mice. In 
communication II, wild-type males of ICR (CD-10) outbred strain were used. In 
communications I and III, transgenic mice heterozygous to reporter construct and 
harboring the chimeric AR (SPARKI) along with their wild-type littermates were used, 
respectively. Mice were orchiectomized under medetomidine-ketamine general 
anesthesia through a lateral incision to scrotum. Hormonal treatments were started four 
days after castration using subcutaneous injections. The androgen dose and the 5-d 
duration of testosterone and genistein administration were chosen on the basis of the 
previous work on androgen action in murine tissues (Kontula et al., 1984; Melanitou et 
al., 1987) and to assure that steady-state conditions were reached. Summary of treatments 
in different experiments is shown in Table 3.  
 
Table 3. Hormonal treatments of mice in the in vivo experiments of communications I, II, and III. 
 
Study Compound Vehicle Dose /  
body weight 
 
Exposure Animals Experiment 
 
I 
 
 
Testosterone 
 
Oil 
 
30 mg / kg 
 
24 h 
 
Castrated 
males 
 
In vivo imaging, ex 
vivo luciferase 
measurement 
 
Testosterone 
 
Oil 
 
30 mg / kg 
 
5 d 
 
Castrated 
males, intact 
females 
 
 
Ex vivo luciferase 
measurement 
 
Genistein 
 
Oil  
2% DMSO 
 
10 mg / kg 
 
5 d 
 
Castrated 
males, intact 
males and 
females 
 
Ex vivo luciferase 
measurement, gene 
expression profiling, 
AR immunoblotting 
 
 
Estradiol 
 
Oil  
0.5% EtOH 
 
10 µg / kg 
 
4 d 
 
Intact males 
 
Gene expression 
profiling 
 
II 
 
Testosterone 
 
Oil 
 
30 mg / kg 
 
2 h 
 
Castrated 
males 
 
Chromatin 
immunoprecipitation 
 
Testosterone 
 
Oil 
 
30 mg / kg 
 
12, 24 h 
3 d 
 
Castrated 
males 
 
Gene expression 
profiling 
 
III 
 
Testosterone 
 
Silastic 
implant 
 
  1 mg / kg 
 
7 d 
 
Castrated 
males 
 
Gene expression 
profiling 
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All in vivo experiments in communications I and II were performed according to the 
guidelines for animal experiments at the University of Helsinki and under license from 
appropriate Finnish Review Board for animal experiments, and in communication III 
with approval of the Katholieke Universiteit Leuven ethical committee. 
1.3 In vivo imaging and ex vivo luciferase assays 
In vivo luciferase activity was monitored using IVIS Imaging System (Caliper 
LifeSciences, Hopkinton, MA). Mice were injected with the luciferase substrate luciferin 
(4.5 mg / mouse in 100 µl of PBS, ip). Imaging was carried out 10 min post-injection in 
dark light-tight chamber with a sensitive charge-coupled device camera under 
medetomidine-ketamine anesthesia. The photon counts were registered for 1 min and 
converted to a pseudocolored image and superimposed on a photographic image of the 
mice using Living Image Software (Caliper LifeSciences).  
 
For protein isolation and ex vivo luciferase assay, tissues were flash-frozen in liquid 
nitrogen immediately after harvesting and stored at −80°C. Frozen tissues were 
homogenized with Ultra Turrax (Ika, Staufen, Germany) in 300 µl of tissue lysis buffer 
containing 100 mM K2PO4 (pH 7.8), 1 mM dithiothreitol, 4 mM EGTA, and 4 mM 
EDTA with a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). 
Homogenates were centrifuged for 30 min at 16,000 × g (4°C), and supernatants were 
used for protein concentration and luciferase activity measurements. Luciferase activity 
was assayed from duplicate samples (20 µl) using Luminoskan Ascent luminometer 
(Thermo Fisher Scientific, Waltham, MA) and 80 µl of luciferin solution (Promega, 
Madison, WI). Protein concentrations were measured using BioRad Reagent (BioRad 
Laboratories, Hercules, CA) according to the manufacturer's instructions. The luciferase 
activities were expressed as relative light units (RLU) per µg of protein. Statistical 
analyses were performed using Student's t test.  
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2. Cell lines and in vitro experiments 
2.1 Cell lines and culture procedures 
Immortalized epithelial cell line from caput epididymis (mE-Cap28 cells) has been 
established from GPX5-Tag1 transgenic mice (Sipilä et al., 2004), and was a kind gift 
from Dr. Petra Sipilä (University of Helsinki, Finland). The cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Life Technologies, Carlsbad, CA) 
in the presence of 10% fetal bovine serum (FBS, Thermo Fisher) and antibiotics 
(penicillin and streptomycin). HeLa cells were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA, USA) and cultured in DMEM containing 4.5 
g/l glucose, 4 mM L-glutamine, and penicillin (100 IU/ml)-streptomycin (100 µg/ml) 
(Sigma-Aldrich, St. Louis, MO), and supplemented with 10% fetal calf serum 
(Invitrogen, Carlsbad, CA). Murine proximal tubule epithelial cells (MRPTEpiCells) 
were purchased from ScienCell Research Laboratories (Carlsbad, CA) and were cultured 
in the growth medium provided by the manufacturer.  
 
Primary culture of proximal tubule epithelial cells from murine kidney was prepared as 
described previously (Asadi et al., 1994). Kidneys were harvested in ice-cold Hank’s 
balanced salt solution (Gibco) and decapsulated. Cortices were dissected and minced with 
scalpel, followed by treatment with collagenase I from Clostridium histolyticum (Gibco) 
in the presence of 0.5% BSA (Fraction V) for 45 min at room temperature. Tubule 
suspension was filtered through wire mesh and centrifuged for 2 min at 60 x g. The pellet 
was washed with and resuspended in the growth medium consisting of 1:1 DMEM/F-12 
(Gibco) supplemented with 0.015 M NaHCO3 (Gibco), 0.1 mM Na-pyruvate (Gibco), 2.5 
mM NaCl, 5 µg/ml bovine insulin (Sigma-Aldrich), 5 µg/ml human transferrin (Sigma-
Aldrich), 50 nM hydrocortisone (Sigma-Aldrich), 1.2 ng/ml epidermal growth factor 
(Gibco), and 10% charcoal-stripped FBS (Thermo Fisher). Tubules were allowed to 
sediment by gravity in growth medium for 10 min. The supernatant was removed, and the 
sediment was resuspended and allowed to sediment for 10 min. Sedimentation was 
repeated four times, and the final sediment was plated on culture dish. The presence of 
tubules in the final sediment was confirmed by microscopic evaluation. 
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2.2 Cell culture experiments 
For ChIP assays, mE-Cap28 and primary kidney cells were seeded in their growth media 
supplemented with 10% charcoal-stripped FBS. After three days, cells were treated with 
100 nM testosterone or vehicle for 2 h. Transactivation experiments were carried out as 
previously described (Verrijdt et al., 2002) in HeLa cells transfected with AR or GR 
expression plasmid (Scheller et al., 1998), luciferase reporter plasmid containing four 
copies of the ARE sequences (communication III), and β-galactosidase expression 
plasmid (Stratagene, La Jolla, CA). Luciferase and β-galactosidase activities were 
measured after a 24-h exposure to 10 nM methyltrienolone (Perkin Elmer, Waltham, 
MA) or dexamethasone (Sigma-Aldrich). 
 2.3 Small interfering RNA (siRNA) transfection  
siRNA transfections were performed to deplete AP-2α from mE-Cap28 cells. Cells were 
seeded in DMEM containing 10% charcoal-stripped FBS, and 70–80% confluent cells 
were transfected with siRNA SMARTpools targeting AP-2α mRNA or non-targeting 
control (Thermo Fisher) with Dharmafect-1 transfection reagent according to the 
manufacturer's instructions. AP-2α mRNA and protein levels were used to monitor 
depletion efficiency and ~80% reduction was observed at 72 h after transfection. ChIP 
assays were performed at 72 h post-transfection using 2-h testosterone treatment (100 
nM). The siRNA sequences are shown in communication II. 
2.4 Electrophoretic mobility shift assay (EMSA)  
AR and GR DBDs were expressed as glutathione S-transferase fusion proteins 
(Schoenmakers et al., 1999). Double-stranded oligonucleotides containing ARE sequences 
(communication III) along with Slp-MUT and Slp-HRE control sequences (Denayer et al., 
2010) were labeled with [α-32P]dCTP and incubated with purified AR DBD or GR DBD 
in 10 mM HEPES (pH 7.9), 2.5 mM MgCl2, 0.05 mM EDTA, 8% glycerol, 50 mM NaCl, 
2.5 ng/µl poly (dIdC), 1 mM dithiothreitol, and 0.05% Triton X-100 for 20 min on ice. 
DBD-bound and unbound probes were resolved on a 4% polyacrylamide gel and bands 
visualized with STORM-840 PhosphorImager (GE Healthcare, Buckinghamshire, UK). 
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3. Gene expression profiling 
3.1 RNA isolation, cDNA synthesis, and qRT-PCR 
Tissues were harvested and stored in RNALater (Qiagen GmbH, Hilden, Germany). Total 
RNA was isolated from the tissues using RNeasy Mini kit and RNeasy Lipid Tissue Midi 
kit (Qiagen) according to the manufacturer’s instructions. cDNA synthesis was carried 
out using 1–2  µg of total RNA with Superscript III First-Strand Synthesis System 
(Invitrogen) or Transcriptor High Fidelity cDNA synthesis kit (Roche) using random 
hexamers. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was 
performed using SYBR Green mastermix (Roche) and 1 µM forward and reverse primers 
in total volume of 20 µl. The results were calculated with LightCycler 480 Software 
(Roche) using standard curve and normalized to 18S rRNA levels. Student’s t test 
(p<0.05 or p<0.001) was used to calculate the statistical significance of differences in 
gene expression in different experimental groups. The primer sequences are provided in 
communications I, II, and III. 
3.2 Microarray experiments 
The RNA integrity values of the samples were > 8, as determined using Agilent 2100 
Bioanalyzer (Agilent, Santa Clara, CA). Direct hybridization assay was performed for 
500 ng of each total RNA sample (n = 3–4 biological replicates per group) using Illumina 
TotalPrep RNA Amplification kit (Ambion, Austin, TX) according to the manufacturer's 
protocol. Biotin-labeled cRNA was hybridized to expression chips using MouseWG-6 v2 
Expression BeadChip kit (Illumina Inc., San Diego, CA). After staining with streptavidin-
Cy3 (GE Healthcare), chips were scanned using iScan System (Illumina) at the 
Biomedicum Functional Genomics core facility. Data analysis was performed using 
Anduril software (Ovaska et al., 2010) and Genomic region operation kit (Ovaska et al., 
2013) together with “R” software and Bioconductor “lumi” package (http://www.r-
project.org/, http://www.bioconductor.org). Raw intensity values were normalized 
independently between arrays for each sample using quantile normalization. The median 
values of sample replicates were used to calculate differentially expressed genes between 
the treatment groups with cut-off values of fold-change ≥1.5 and a p-value < 0.05 
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(Student’s t test). Unsupervised hierarchical clustering and heat maps were generated 
using Cluster and TreeView (Eisen et al., 1998). 
3.3 Immunoblotting  
Proteins were extracted from frozen tissues and protein concentrations determined as 
described in Chapter 1.3. Cells were lysed in a buffer containing 50 mM Tris-HCl (pH 
7.8), 150 mM NaCl, 15 mM MgCl2, 5 mM EDTA, 0.5% Nonidet P-40, 0.3% Triton X-
100, and complete protease inhibitor set (Roche). Fifty µg of total protein from tissues or 
from mE-Cap28 and primary kidney cells was resolved on a 7.5% or 10% SDS-PAGE 
(BioRad) and transferred onto enhanced chemiluminescence (ECL) membrane (GE 
Healthcare). The specific antibodies used in immunoblotting are described in 
communications I and II. The immune complexes were detected with horseradish 
peroxidase-conjugated secondary antibodies and visualized with ECL reagent (GE 
Healthcare) and were scanned and quantified by using the ImageJ program in 
communication I.  
 3.4 Immunohistochemistry 
Prostate, kidney, and caput epididymis tissues were collected from intact male mice and 
fixed in 4% paraformaldehyde at 4°C overnight, dehydrated, and embedded in paraffin. 
Five-µm sections were dewaxed with xylene, rehydrated, and treated with 2% hydrogen 
peroxide for 15 min to block the endogenous peroxidase activity. For antigen retrieval, 
the slides were boiled in 10 mM sodium citrate (pH 6.0). The blocking was performed in 
1% bovine serum albumin and normal goat or horse serum (Vector Laboratories, 
Burlingame, CA), and incubation with primary antibodies (communication II) was 
carried out in 1:200 dilution at 4°C overnight. Biotinylated anti-rabbit and anti-mouse 
IgG secondary antibodies (Vector Laboratories) were used in 1:200 dilution, and the 
immune complexes were visualized using the Vectastain Elite ABC and DAB substrate 
kits (Vector Laboratories). Counterstaining was carried out using Mayer's hemalum 
solution (Merck, Darmstadt, Germany). The slides were dehydrated and mounted using 
Permount (Fisher Chemicals, Fair Lawn, NJ). 
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4. Genome-wide analysis of transcription factor binding 
4.1 Chromatin immunoprecipitation (ChIP) and ChIP-qPCR 
In ChIP assays, testosterone- or vehicle-treated cells or tissues from intact or testosterone- 
or vehicle-treated castrated male mice were used. Testosterone-treatment of 2 h was used 
for both cells (100 nM) and mice (1 mg in 100 µl mineral oil, ip). Cells were cross-linked 
in 1% formaldehyde for 10 min at room temperature, washed with ice-cold PBS and 
scraped in Farnham lysis buffer as previously described (Sahu et al., 2011). Cell pellet 
was resuspended in 300 µl RIPA buffer containing protease inhibitors and sonicated to 
100–500-bp chromatin fragments with Bioruptor (Diagenode, Liege, Belgium). Fresh 
tissues were minced with a scalpel, and frozen tissues were pulverized before 20 min 
cross-linking (1% formaldehyde, room temperature). Cross-linking was stopped by using 
0.125 M glycine for 5 min at room temperature, followed by two washes with ice-cold 
PBS. The cross-linked tissues were homogenized in hexylene glycol buffer containing 1 
M hexylene glycol, 0.1 mM MgCl2, 5 mM EGTA, 1 mM PIPES, 2 mM dithiothreitol, 
and complete protease inhibitor set (Roche) using Ultra Turrax (Ika), and the homogenate 
was filtered through nylon net (Isomaa et al., 1982). To isolate crude nuclear fraction, the 
filtered homogenate was centrifuged, and the pellet was resuspended in 500 µl RIPA 
buffer. Chromatin was sonicated to yield fragments of 100–500 bp in size using a micro-
tip sonicator (Misonix Inc., Farmingdale, NY).  
 
For a single immunoprecipitation reaction, 100 µl chromatin from cells or tissues was 
used. Antibodies conjugated to magnetic Dynabeads (Invitrogen) were incubated at 4°C 
with sonicated chromatin overnight, followed by five washes in LiCl wash buffer and 
reverse cross-linking at 65°C for 15 h. Immunoprecipitated DNA was purified using 
Qiaquick PCR purification kit (Qiagen) and eluted in 100 µl of elution buffer. In ChIP-
qPCR, immunoprecipitated and input DNA was amplified using SYBR Green Mastermix 
(Roche) and specific primers, and the results were shown as % of input values. Details of 
the antibodies and primer sequences are provided in communications II and III. 
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4.2 ChIP-sequencing  
Immunoprecipitated DNA samples were processed for library preparation according to 
Illumina’s instructions as described previously (Sahu et al., 2011), by pooling three to 
four immunoprecipitates for each library. In brief, the DNA samples were blunt-ended 
and ligated to sequencing adapters. Adapter-ligated DNA fragments (size range, 150–300 
bp) were excised from agarose gel and purified with QIAquick Gel Extraction kit 
(Qiagen). Isolated DNA was amplified by PCR (20 cycles), and the purified DNA library 
was sequenced using Genome Analyzer II (Illumina) at Biomedicum Functional 
Genomics core facility. ChIP-seq reads were filtered using the Illumina chastity filter 
during the base-calling process and the reads were aligned to reference mouse genome 
(mm9) using Bowtie, without any mismatches. ChIP-seq experiments were performed in 
biological duplicates, and only reproducible peaks were used for further analyses.  
4.3 Bioinformatics analyses of ChIP-seq data 
ChIP-seq peak calling and differential peak calling were performed using MACS version 
1.4, MACS2 (Feng et al., 2012; Zhang et al., 2008) and HOMER (Heinz et al., 2010) 
algorithms. The overlap analysis, CEAS analysis, genome-wide correlation, motif 
analysis, and tag density maps were performed using Cistrome: an integrative platform 
for transcription regulation studies (Liu et al., 2011). In communication II, de novo and 
motif enrichment analyses for top-enriched 5,000 AR ChIP-seq peaks unique to each 
tissue were performed using SeqPos motif tool in Cistrome, and the results were sorted 
on the basis of z-score. De novo motifs were identified using TOMTOM motif 
comparison tool in MEME Suite (Gupta et al., 2007). Find Motif algorithm in HOMER 
analysis suite (Heinz et al., 2010) was used for motif scanning among all AR-binding 
sites in each tissue, and for de novo analysis in communication III along with MEME 
Suite (Bailey et al., 2009). Data visualization was carried out using Integrative Genomics 
Viewer (Robinson et al., 2011b). 
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RESULTS AND DISCUSSION 
1. Generation of the androgen reporter mouse model (Communication I) 
1.1 Generation of the transgenic reporter mouse model 
Generation of transgenic estrogen reporter mouse lines ten years ago demonstrated the 
potential of using in vivo imaging to study steroid receptor function in live mice (Ciana et 
al., 2003; Lemmen et al., 2004). In this thesis work, the first androgen reporter mouse 
suitable for in vivo imaging in multiple tissues was described – the previous models for 
AR were either designed for reporter expression in prostate only or used LacZ reporter 
that needs to be detected with staining rather than imaging (Iyer et al., 2005; Lyons et al., 
2006; Xie et al., 2004; Ye et al., 2005). The androgen reporter construct containing 
luciferase reporter gene driven by four copies of the AR-selective Slp-HRE2 response 
elements (Verrijdt et al., 2000) and thymidine kinase minimal promoter was integrated to 
mouse genome by pronuclear injection technique. MAR-insulator sequences (Phi-Van et 
al., 1990) were introduced to the construct to minimize potential position effects of the 
genomic integration site on reporter gene expression. In this model, luciferase expression 
is a measure of androgen action via AR. Luciferase is a well-suited reporter for in vivo 
studies due to its low background activity in mammals in bioluminescent imaging and 
easily quantifiable and sensitive enzymatic assay for ex vivo measurements (Ottobrini et 
al., 2006). The progeny of fourteen founder animals that had the reporter construct 
integrated into their genome was screened for luciferase expression in different tissues. 
The mouse line with the greatest number of androgen-responsive tissues reproducible 
expressing the luciferase reporter gene was selected for further studies. 
1.2 Validation of the androgen reporter mouse 
Luciferase expression was detected in several tissues in intact male and female mice of 
the reporter mouse line, including skeletal muscle, brain, and lung. The highest values for 
luciferase activity were observed in skeletal muscle in females and prostate in males. 
Testosterone administration induced reporter gene activity, as judged by in vivo imaging 
and ex vivo luciferase measurements from testosterone-treated castrated males and intact 
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females when compared to vehicle-treated controls (Figure 8). Interestingly, reporter 
activity in lungs of castrated males was androgen-induced, and this observation led to 
further characterization of AR action in lung and identified lung as a novel androgen 
target tissue (Mikkonen et al., 2010).  
 
Figure 8. Androgen-induced luciferase activity measured in vivo using sensitive charge-coupled 
device camera (A) and by enzymatic ex vivo assay (B) from tissues of testosterone-treated 
castrated males and intact females. 
 
Despite the insulator sequences flanking the reporter construct, luciferase expression was 
not detected in some known androgen-target tissues, such as liver and kidney. Random 
genomic integration after pronuclear DNA injection might result in transgene localization 
at a site where the local genomic environment is not favorable for luciferase expression 
or its androgen regulation. Recently, another androgen reporter mouse line was described 
(Dart et al., 2013). In this case, the reporter construct was targeted to the hypoxanthine 
phosphoribosyltransferase (Hprt) gene locus that provides an open chromatin 
environment for targeted transgene expression (Bronson et al., 1996). This latter mouse 
line showed a broader range of tissues with detectable luciferase activity, attesting to the 
effect of genomic environment for transgene expression. Nevertheless, our reporter 
mouse showed robust, reproducible, and androgen-responsive reporter expression in 
several important AR-target tissues, including prostate, skeletal muscle, testis, and brain, 
and it was well-suited for studying tissue-specific in vivo effects of chemical compounds 
or other conditions of interest.   
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2. Genistein as a novel androgen receptor modulator (Communication I) 
2.1 Genistein affects reporter gene activity in a tissue-specific manner 
Genistein, a polyphenolic phytoestrogen present in soy, is a bioactive compound with 
estrogenic effects in cells  (e.g., Chang et al., 2008) and tissues (e.g., Moggs et al., 2004; 
Thomsen et al., 2006). Considerable amount of genistein is found in circulation of 
individuals consuming soy products, up to 2.5 µM in plasma of soy-based formula-fed 
infants (Setchell et al., 1997). Genistein is an interesting compound in terms of cancer 
prevention due to its effects on steroid hormone signaling and epidemiological evidence 
for low incidence of hormonal cancers in soy-consuming Asian countries (Jian, 2009). 
 
Androgen reporter mice were exposed to five-day treatment with genistein to examine its 
in vivo effects on AR signaling at a dose relevant in humans on a soy-rich diet. In the 
presence of physiological androgens, genistein decreased luciferase activity in prostate, 
brain, and testis without affecting AR protein amount, when compared to intact vehicle-
treated mice. However, under androgen-deprived conditions, genistein had an agonistic 
effect on AR function in prostate and brain (Figure 9A). Reporter activity in skeletal 
muscle and lung was unaffected by genistein treatment, demonstrating the tissue-selective 
nature of genistein action. According to an in silico docking model, genistein fits to the 
AR ligand-binding pocket (Wang et al., 2010); however, there are conflicting reports on 
genistein bioactivity in androgen reporter model systems in vitro (Bovee et al., 2008; 
Takahashi et al., 2004; Takeuchi et al., 2009). Our results provided evidence for genistein 
modulating AR signaling under in vivo conditions in a tissue-specific manner. 
2.2 Genistein affects endogenous gene expression profile in prostate 
Genistein effect on expression profiles of endogenous genes was assessed using gene 
expression microarray. With a fold change ≥1.5 (p < 0.05), 146 and 307 transcripts were 
differentially expressed in response to genistein treatment in prostates of intact and 
castrated mice, respectively. In intact prostate, two thirds of transcripts regulated by 
genistein were also androgen-dependent, strongly supporting the notion that genistein 
affects gene expression by modulating AR activity. In most cases in intact prostate, 
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genistein effect on gene expression was opposite to that of androgen (Figure 9B). By 
contrast, genistein had more androgen-like effects in the prostates of castrated males 
(Figure 9B). Genistein is also able to affect estrogen signaling, but a greater proportion of 
genistein-regulated genes in murine prostate overlap with AR transcriptional program 
compared to that of ER, implying that the effects of genistein on androgen signaling in 
mouse prostate are unlikely to involve ER activation. Interestingly, genistein-treatment 
has been shown to bring about thousands of ERα-binding events in breast and uterine 
carcinoma cell lines (Gertz et al., 2012). Delineation of genistein-induced AR cistrome in 
murine prostate would complement the transcription profiles obtained in the present 
study. Although genistein can also modulate growth factor receptor functions, inhibition 
of receptor tyrosine kinases requires much higher circulating genistein levels than the one 
used in the present study (Akiyama et al., 1987). 
 
In conclusion, genistein elicits both agonistic and antagonistic effects on AR-regulated 
gene expression. Of note, a recent study reported that AR mutations change the 
agonistic/antagonistic effects of genistein in prostate cancer cell lines (Mahmoud et al., 
2013), which might explain previous controversial results in studies using cell lines. The 
strength of our study is, however, the use of physiological in vivo environment with 
multiple cell types within the normal tissue structure together with the intact AR pathway 
containing endogenous coregulators and collaborating factors.  
 
 
Figure 9. The effect of genistein on androgen-induced luciferase activity measured by enzymatic 
ex vivo assay in five different tissues of castrated and intact males (A) and on endogenous gene 
expression profiles in prostates of castrated and intact males (B).   
  Results and discussion 
 
 
 
 
59 
3. Characteristics of the AR pathway in vivo (Communications II and III) 
3.1 In vivo AR cistromes are highly tissue-specific 
Seminal papers using chromatin immunoprecipitation coupled with high-throughput 
sequencing from mouse tissues have demonstrated the power of ChIP-seq in studying 
tissue-specific transcription factor binding and chromatin modifications in vivo (Shen et 
al., 2012; Visel et al., 2009). However, despite numerous AR cistromes reported for 
prostate cancer cell lines, only few genome-wide AR binding profiles in tissues have 
been described. The first in vivo AR cistrome was reported for mouse epididymis (Hu et 
al., 2010), and subsequently, AR binding has been examined in the context of murine 
liver and prostate carcinogenesis (Chen et al., 2013; Li et al., 2012b) and in primary 
myoblasts (Wyce et al., 2010). Recent study also described AR binding profiles in 
prostate cancer patient samples (Sharma et al., 2013), but comprehensive analyses of AR 
cistromes and transcriptional programs under physiological conditions have been lacking.  
 
In this thesis work, AR cistromes were determined for three androgen-responsive tissues 
– prostate, kidney, and epididymis – in castrated and androgen-treated male mice 
utilizing the ChIP-seq approach. High-quality data of in vivo AR occupancy was obtained 
with excellent reproducibility of two biological replicate samples and robust androgen-
induced binding profiles. With stringent analysis parameters (false discovery rate < 2%, 
peak present in two biological replicates), 10,171 AR chromatin binding events in 
prostate, 14,062 in kidney, and 22,598 in caput epididymis were detected. Importantly, 
there was no significant chromatin AR binding in the absence of androgens. AR 
cistromes are highly tissue-specific: only a small proportion (7–16%) of AR-binding 
events were shared between all three tissues, and the majority of the binding events were 
unique to a given tissue (Figure 10A). The highest number of overlapping binding events 
was observed between the two reproductive tissues, prostate and epididymis. Previous 
studies reporting cell type-specific cistromes for ERα and PR have been based on 
cultured cancer cell lines (Gertz et al., 2013; Krum et al., 2008; Yin et al., 2012). AR 
cistromes obtained in our study under physiological conditions in live animals confirm 
that steroid receptor cistromes are highly tissue-specific. 
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3.2 AR regulates distinct cellular pathways in different tissues 
Androgen-regulated transcripts in prostate, kidney, and epididymis were determined by 
microarray analysis at three different time intervals after testosterone exposure – 12 and 
24 hours and 3 days – to obtain a comprehensive view of the AR transcriptome. At each 
time point, hundreds of differentially expressed transcripts were identified when castrated 
testosterone- and vehicle-treated mice were compared (fold change ≥ 1.5, p < 0.05). 
Importantly, AR regulates distinct transcription programs in different tissues: the majority 
of both up- and down-regulated transcripts are unique to each tissue, and only a few 
common genes are similarly regulated in all three tissues (Figure 10B). Interestingly, 
unsupervised hierarchical clustering revealed that there are transcripts up-regulated by 
androgen in one tissue, but down-regulated in another (Figure 10C), attesting to the 
context-specificity of androgen-dependent transcriptional regulation.  
 
Enrichment analysis of gene ontology categories was performed for differentially 
expressed gene categories after a three-day testosterone-treatment. Various metabolic 
pathways are under androgenic control especially in kidney. Importantly, androgen-
induced transcripts in prostate and epididymis but not in kidney are over-represented for 
genes involved in cell cycle regulation and mitosis. This agrees with the previous notion 
that androgen exposure increases hypertrophy but not hyperplasia of renal proximal 
tubule cells (Bardin and Catterall, 1981). In prostate, on the other hand, both epithelial 
and stromal AR contribute to the epithelial proliferation, as judged from the phenotypic 
changes in cell type-specific ARKO mice (Simanainen et al., 2007; Wu et al., 2007; Yu 
et al., 2011). 
 
Androgen-regulated transcripts in each tissue were mapped to the AR-binding events. 
The majority of the differentially expressed genes in each tissue and at every time point 
have at least one AR-binding site within ±100 kb of the transcription start sites, 
confirming androgen-regulation of these transcripts and validating the accuracy of the 
ChIP-seq data. Both up- and down-regulated genes in each category could be mapped to 
the nearest AR-binding event statistically more often than stably expressed genes after 
testosterone exposure (Figure 10D). 
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3.3 Selective AREs guide AR binding to specific enhancers in vivo 
All NR3C family steroid receptors – AR, GR, MR, and PR – bind to and transactivate via 
the classical androgen/glucocorticoid response element (AGE/GRE), an inverted repeat 
of the 5’-AGAACA-3’ sequence, but the so-called selective AREs can only be bound by 
AR and not by GR (Denayer et al., 2010). Previous studies have shown that AR and GR 
bind to shared loci on native chromatin in cancer cells (John et al., 2011; Sahu et al., 
2011; Sahu et al., 2013). Ligand-occupied GR is able to modulate the AR pathway and 
maintain the expression of AR-regulated genes under androgen-deprived conditions 
(Arora et al., 2013; Sahu et al., 2013). This phenomenon is of clinical importance since 
cancer cells of prostate cancer patients on AR-suppressing drugs are potentially able to 
bypass the AR blockade through GR action. Importantly, more than half of prostate 
carcinomas from patients treated with androgen deprivation therapy express GR 
(Yemelyanov et al., 2012), and glucocorticoids are currently administered to abiraterone-
treated prostate cancer patients to avoid side effects from CYP17 inhibition (Attard et al., 
2012).  
 
The chimeric AR with its second zinc finger replaced with that of GR binds only to 
classical AREs (Schoenmakers et al., 1999). Knock-in mice with this chimeric AR, 
termed SPARKI mice, have smaller reproductive organs than the wild-type littermates 
and are hypofertile (Kerkhofs et al., 2012; Schauwaers et al., 2007). In the present study, 
the importance of the receptor DBD for chromatin binding in vivo was studied by 
examining the SPARKI AR cistrome and by comparing it to that of wild-type AR in 
murine epididymis and prostate. Both tissues showed distinct binding profiles for wild-
type and SPARKI ARs (Figure 10E), and there are three categories of AR-binding events 
in vivo. Shared loci are bound by both SPARKI and wild-type AR with a similar affinity. 
Wild-type AR-preferred binding events – 55 and 50% of the epididymal and prostatic AR 
cistromes, respectively – comprise the AR-selective enhancers in vivo, and SPARKI AR 
is recruited to these sites with lower affinity (Figure 10E). Surprisingly, there are also 
SPARKI AR-preferred loci that wild-type AR binds with blunted affinity. Although 
mechanistic determinants for enhanced recruitment of SPARKI AR to this subset of loci 
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remain elusive, they are likely due to the local chromatin environment and/or differential 
interactions with coregulators (Wiench et al., 2011b).  
Importantly, differential AR binding in vivo was associated with significant changes in 
transcription programs. According to gene expression microarrays, there are 219 
androgen-dependent transcripts in epididymis with differential expression in SPARKI 
mice compared to wild-type mice (fold change ≥ 1.5, p < 0.05) (Figure 10F). In 
conclusion, selective AREs play a significant role in genome-wide AR binding in two 
reproductive tissues, prostate and epididymis, agreeing with the hypofertile phenotype of 
the SPARKI males (Schauwaers et al., 2007). 
 
 
Figure 10. A. Area-proportional Venn diagram of AR-binding events in prostate, kidney, and 
epididymis after a 2-h androgen treatment. B. Transcripts up- and down-regulated in prostate, 
kidney, and epididymis after a 3-day androgen exposure. C. Unsupervised hierarchical clustering 
of androgen-regulated transcripts in prostate, kidney, and epididymis. D. Mapping of androgen-
regulated genes to AR-binding events within ±100 kb from transcription start sites. E. Area-
proportional Venn diagrams of AR-binding events in prostate and epididymis of wild-type and 
SPARKI mice. F. Unsupervised hierarchical clustering of androgen-regulated and differentially 
expressed transcripts in epididymis of wild-type and SPARKI mice.  
  Results and discussion 
 
 
 
 
63 
4. Determinants of context-specific AR binding (Communications II and III) 
4.1 Distinct pioneer factors guide tissue-specific AR binding in vivo 
To investigate the cellular determinants for tissue-specific AR binding, de novo and motif 
enrichment analyses were performed for all prostate-unique and top 5,000 of kidney and 
epididymis-unique AR-binding events. Interestingly, de novo analysis identified distinct 
cis-elements enriched among AR binding events: FoxA1 in prostate, hepatocyte nuclear 
factor 4 alpha (Hnf4α) in kidney and AP-2α in epididymis, suggesting that these factors 
bind to the sites shared with AR in a tissue-specific manner. Indeed, ChIP-seq carried out 
for these transcription factors in prostate, kidney and epididymis revealed significant 
overlap for AR and FoxA1 cistromes in prostate, AR and Hnf4α cistromes in kidney, and 
AR and AP-2α cistromes in epididymis (Figure 11A). Of note, there is no FoxA1 binding 
in kidney and epididymis nor Hnf4α binding in prostate and epididymis (Figure 11B). A 
small number of AR-binding events overlap with AP-2α binding in prostate and kidney, 
but the number is considerably lower than the overlapping sites with FoxA1 or Hnf4α, 
respectively. ARE cis-elements were also found to be significantly enriched among the 
tissue-specific AR-binding events in prostate, kidney, and epididymis. The situation 
appears to be different in the case of ERα, with cell type-specific ER cistromes having 
only weak ER-response elements in breast and uterine cancer cell lines (Gertz et al., 
2013). 
 
In order to serve as pioneer factors for AR, tissue-specific collaborating factors should 
occupy the enhancers already prior to androgen-induced AR binding. ChIP-seq from the 
tissues of castrated males confirmed that FoxA1 in prostate, Hnf4α in kidney, and AP-
2α in epididymis bind to chromatin in the absence of androgen and potentially prime it 
for subsequent AR binding (Figure 11B). Furthermore, a greater proportion of enhancers 
shared by AR and FoxA1 in prostate, AR and Hnf4α in kidney, and AR and AP-2α in 
epididymis reside in an open chromatin environment marked by H3K4me1 and K3K27ac 
histone modifications than the AR only sites, further attesting to the functional 
significance of these shared sites as transcriptionally active enhancers (Figure 11C). 
Immunohistochemical antigen staining confirmed that the tissue-specific collaborating 
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factors, that is, FoxA1 in prostate, Hnf4α in kidney, and AP-2α in epididymis, are 
expressed in the same cell types as AR. 
 
Figure 11. A. Area-proportional Venn diagrams of AR-binding events with tissue-specific 
pioneer factors FoxA1 in prostate, Hnf4α in kidney, and AP-2α epididymis after 2-h androgen 
treatment. B. Tag density maps of AR, FoxA1, Hnf4α, and AP-2α in prostate, kidney and 
epididymis. C. Average tag profiles of ChIP-seq tags for H3K4me1 histone modification in 
shared AR-FoxA1 and AR only sites in prostate, in shared AR-Hnf4α and AR only sites in 
kidney, and shared AR-AP-2α and AR only sites in epididymis. 
 
 
The pioneering role for FoxA1 is well-established in prostate cancer cell lines (Lupien et 
al., 2008; Sahu et al., 2011), and our in vivo results from murine prostate confirm that 
observation. Other pioneer factors suggested for AR in prostate cancer cell lines include 
GATA and ETS factors (Chen et al., 2013; Chng et al., 2012; Massie et al., 2007; Wang 
et al., 2007; Wu et al., 2014; Yu et al., 2010). Our results revealed two novel pioneer 
factors for AR, Hnf4α in kidney and AP-2α in epididymis, and underline that FoxA1 is 
not a universal, but rather a prostate-specific pioneer factor for AR. To confirm further 
that AR binding is dependent on these novel factors, immortalized murine epididymal 
cell line depleted of AP-2α using specific siRNA, and primary epithelial cells from renal 
proximal tubules inherently devoid of Hnf4α, were used in ChIP assays. Attenuation of 
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AR binding was observed under these depletion conditions at the loci shared by AR and 
Hnf4α and AR and AP-2α in these renal and epididymal cell lines. AP-2γ was recently 
identified as pioneer factor for ER in breast cancer cells (Tan et al., 2011). AP-2γ is not 
expressed in murine epididymis, but another member of the same protein family, AP-2β, 
may also play a role in epididymal AR binding (Hu et al., 2010). Hnf4α is a 
constitutively active nuclear receptor that has not been previously linked to AR function. 
However, Hnf4α is reported to be required for small heterodimer partner (SHP) binding, 
and liver-specific depletion of Hnf4α results in reduction in H3K4 trimethylation (Kir et 
al., 2012). Interestingly, Hnf4α depletion has more prominent effects on gene expression 
in liver of male mice compared to females (Holloway et al., 2008), but its role in AR 
signaling in tissues other than kidney remains to be elucidated. 
 
The idea that distinct pioneer factors dictate cell type-specific steroid receptor cistromes 
has been suggested on the basis of the results acquired from the cancer cell lines (Krum et 
al., 2008). However, overlapping steroid receptor and pioneer factor cistromes have been 
produced mostly from breast and prostate cancer cell lines for ER and AR, respectively 
(cf. Table 2). Although collaborating factors other than FoxA1 have been discovered, 
many of these novel factors are also linked to steroid receptor function in the same cell 
types, such as GATA-3 and AP-2γ for ERα function in breast cancer cells (Gertz et al., 
2013; Tan et al., 2011; Theodorou et al., 2013) and GATA-2 and ETS factors for AR 
function in prostate cancer cells (Massie et al., 2011; Wu et al., 2014). Furthermore, 
several studies that have suggested differential pioneer factor involvement have merely 
reported differential cis-element enrichment around receptor-binding events, not taking 
into account whether the suggested factors actually bind to these sites, or are even 
expressed in the cell types in question (Lain et al., 2013; Rubel et al., 2012; Yin et al., 
2012). In summary, this thesis work on androgen receptor binding in multiple tissues and 
under physiological conditions in vivo emphasizes the role of distinct pioneer factors for 
tissue-specific AR cistromes (Figure 12). This concept is likely to apply to other steroid 
receptors as well. However, pioneer factors for AR in tissues other than those 
investigated in the present work, and for other steroid receptors in their multiple target 
tissues remain to be discovered.  
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Figure 12. Schematic representation of the role of distinct pioneer factors in tissue-specific AR 
binding and transcriptional regulation. 
 
4.2 Selective AREs exhibit relaxed sequence stringency in vivo 
In vivo AR cistromes revealed three categories of AR-binding events: wild-type AR-
preferred, SPARKI AR-preferred, and shared sites bound by both receptors with similar 
affinity. In order to study the DNA sequence of the cis-elements enriched for these three 
categories, de novo motif search was performed. As expected, canonical ARE/GRE, an 
inverted repeat of the 5'-AGAACA-3' hexamer, was enriched among the shared AR-
binding sites, i.e., the sites that both wild-type and SPARKI AR are able to bind (Figure 
13). A similar motif was also present among the SPARKI AR-preferred sequences. 
Strikingly, the cis-element enriched among wild-type AR-preferred sequences in both 
prostate and epididymis showed very weak sequence conservation in the second hexamer 
(Figure 13). These results suggest that AR-selective receptor binding in vivo is achieved 
through relaxed cis-element stringency rather than any exact ARE sequence. Thus, the 
previous concept that DNA sequence of selective AREs is a direct repeat of the 5'-
AGAACA-3' sequence (Denayer et al., 2010; Helsen et al., 2012; Verrijdt et al., 2000) is 
not a general rule of AR-selectivity. However, due to the relaxed sequence requirement 
for the second hexamer, a selective ARE can potentially also resemble a direct repeat. 
Interestingly, the middle nucleotide in the spacer displays sequence conservation and 
enrichment of an adenine over other nucleotides among shared and SPARKI AR-
preferred sites in prostate (Figure 13B). The importance of the spacer sequence was 
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recently demonstrated in a report showing that the nucleotides in the GRE spacer affect 
GR DBD conformation and its DNA-binding affinity (Watson et al., 2013). 
 
Figure 13. Cis-elements identified by de novo motif analysis within AR-binding sites shared by 
wild-type and SPARKI AR, and for SPARKI AR-preferred and wild-type AR-preferred sites in 
epididymis (A) and prostate (B). 
 
The first zinc finger in the steroid receptor DBD is responsible for the sequence-specific 
DNA contact, and the second zinc finger – the part that differs between wild-type and 
SPARKI AR – is responsible mainly for receptor dimerization. Compared to the GR 
DBD, the amino acid residues in the AR DBD allow stronger affinity at the dimer 
interface (Luisi et al., 1991; Shaffer et al., 2004). This phenomenon potentially explains 
why the sequence of the second hexamer is less important for AR binding, since a 
stronger receptor dimerization would allow selective AR binding to AREs that GR cannot 
bind. Moreover, single amino acid insertion in GR dimer interface has been reported to 
lead to redistribution of GR binding in a genome-wide scale (Thomas-Chollier et al., 
2013). 
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FUTURE PERSPECTIVES  
ChIP-seq is a powerful method for studying chromatin-associated proteins and covalent 
modifications, as demonstrated by the wealth of data generated over the past decade 
using next-generation sequencing approaches. However, genome-wide mapping of 
receptor occupancy is just the first step towards more comprehensive understanding of 
transcriptional regulation. The ENCODE Project Consortium has produced detailed maps 
of gene regulatory elements in a wide range of cell types and commenced systematic 
analyses of the architecture of transcriptional networks. Nevertheless, assigning defined 
sets of regulatory elements to a particular transcription unit is a challenge that requires 
further research efforts and development of new methodology, such as the novel genome 
editing tools.  
 
Few recent reports have initiated functional characterization of the distal transcription 
factor-binding sites. First, a polymorphic enhancer residing 335 kb upstream of the Myc 
oncogene was deleted in mice leading to a decrease in Myc expression and resistance to 
intestinal tumorigenesis (Sur et al., 2012). Second, novel technology combining 
transcription activator-like (TAL) effectors with LSD1 was used to demethylate lysines at 
specific enhancer region of stem cell leukemia locus leading to decreased expression of 
proximal genes (Mendenhall et al., 2013). Furthermore, interactome maps have revealed 
physical connections and chromosome conformation within the genome (Kieffer-Kwon et 
al., 2013), and analyses of DNase I-hypersensitivity sites recently uncovered 
asymmetrical chromatin opening by a subset of pioneer factors (Sherwood et al., 2014). 
Information pertaining to transcription factor binding and genetic polymorphisms 
combined with methodological advancements is anticipated to lead to elucidation of 
novel features and functional relationships between distal enhancers and transcriptional 
regulation.  
 
Many of the pioneer factors identified for steroid receptors, such as FoxA1, Hnf4α, and 
AP-2α that were studied in this thesis work, are crucial regulators of embryonic 
development and organogenesis. Thus, knocking out of the genes encoding these factors 
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in mice results in embryonically lethal phenotypes. It would be interesting to study the 
effects of cell type-specific or inducible depletion of these factors on the AR pathway in 
vivo. Furthermore, despite recent reports characterizing chromatin landscape associated 
with transcriptional regulation, the mechanisms that determine pioneer factor binding are 
still elusive and intriguing questions persist. Do pioneer factors recognize a specific 
histone code and, if yes, how is the code established? Is there a functional hierarchy 
between collaborating pioneer factors? Do pioneer factors have redundant functions? 
What initiates and regulates specific pioneer factor function during development? And 
finally, what is the full spectrum of pioneer factor effects on steroid receptor signaling? 
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SUMMARY AND CONCLUSIONS 
Genome-wide technologies for mapping transcription factor binding events, chromatin 
modifications, and gene expression profiles have revealed novel features of 
transcriptional regulation. The core of steroid receptor function – hormone-induced DNA 
binding of a ligand-occupied receptor – is necessary but not sufficient for physiological 
hormone action in a native chromatin environment. Collaborating transcription factors 
and the coregulatory proteins along with local chromatin features, such as histone 
modifications, facilitate context-specific transcriptional outcome. Distinct AR cistromes 
in three androgen-responsive tissues – prostate, kidney, and epididymis – established in 
this thesis work have contributed to our understanding of tissue-specific androgen-
dependent gene regulation. Two novel pioneer factors for AR were identified, Hnf4α in 
kidney and AP-2α in epididymis. The role of DBD in and of itself in specifying receptor-
binding events was studied using transgenic SPARKI mouse model that expresses 
chimeric AR, the second zinc finger of which is replaced with that of GR. SPARKI AR 
fails to bind or binds with attenuated affinity to wild-type AR-preferred genomic loci. 
Sequence analysis of these selective enhancers was used to determine characteristic 
features of AR selectivity in vivo. 
 
Naturally occurring dietary chemicals with the ability to modulate steroid hormone 
signaling are promising compounds in prevention of hormone-dependent cancers. Several 
lines of evidence from epidemiological studies and murine models link phytoestrogen 
genistein to prostate cancer risk and disease progression. Our findings support the 
potential role of genistein in prostate cancer prevention, in that it modulates AR-mediated 
gene expression in vivo in a tissue-specific and context-dependent manner at a dose 
relevant to human exposure on soy-rich diet. However, overall cancer risk of an 
individual is determined by a combination of genetic and environmental factors, 
including dietary compounds.  
 
Collectively, this thesis work provided novel insights into AR function in vivo. The main 
conclusions are as follows: 
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1. An androgen reporter mouse with robust androgen-responsive reporter gene 
expression in multiple tissues was generated. It was a useful tool for delineating 
the effects of chemical compounds perturbing with AR signaling in vivo. 
 
2. Genistein is a tissue-specific androgen receptor modulator that exhibits both 
agonistic and antagonistic effects on AR signaling in prostate and brain but not in 
lung or skeletal muscle in vivo. 
 
3. Divergent AR cistromes in three murine androgen-responsive tissues – prostate, 
kidney, and epididymis – drive androgen-dependent tissue-specific 
transcriptional programs. 
 
4. Distinct tissue-specific pioneering/licensing factors – FoxA1 in prostate, Hnf4α 
in kidney, and AP-2α in epididymis – guide AR-binding events in different 
tissues, and the enhancers shared by AR and these factors associate with active 
chromatin marks. 
 
5. The second zinc finger in the AR DBD directs AR binding to selective androgen 
response elements on prostatic and epididymal chromatin. Distinct cistromes of 
wild-type and SPARKI AR are associated with differential transcriptional 
outcomes in vivo. 
 
6. Selectivity of AR binding to chromatin over other steroid receptors is achieved 
by less stringent requirement for the cis-element DNA sequence. 
 
7. Overall, the results clarified several molecular mechanisms employed by AR in 
vivo and provided important mechanistic insights that are potentially important 
for the development of better treatments and diagnostic tools for hormone-
dependent disorders. 
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